<html lang="en" class="pb-page js" data-request-id="94d63293d0ae0308-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d63293d0ae0308-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/dDzXNqQgyXbzDp9Ys_6U9wRVnLLT1p4De4Q0sn7b-FS_Qtfz6xcmSFPKObnNPw0S8aZtwiFTgTJfIt0-eUYK9g=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d63293d0ae0308-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.39449254413441415"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Infectious Disease">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Tuberculosis|Diagnostics|HIV/AIDS"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1910708","title":"Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults","category":"Research","type":"Original Article","topics":"Tuberculosis|Diagnostics|HIV/AIDS","specialties":"Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-06-18T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Tuberculosis|Diagnostics|HIV/AIDS\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1910708","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Visual Abstract","title":"Systematic or Test-Guided Treatment for TB in HIV","doi":"10.1056/NEJMdo005793","issueDate":"2020-06-18T00:00Z","age":"6Months-1990","isFree":"y","topics":"Tuberculosis|Diagnostics|HIV/AIDS","viewType":"Full","specialties":"Infectious Disease"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d63293d0ae0308-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults"><meta name="dc.Creator" content="François-Xavier Blanc"><meta name="dc.Creator" content="Anani D. Badje"><meta name="dc.Creator" content="Maryline Bonnet"><meta name="dc.Creator" content="Delphine Gabillard"><meta name="dc.Creator" content="Eugène Messou"><meta name="dc.Creator" content="Conrad Muzoora"><meta name="dc.Creator" content="Sovannarith Samreth"><meta name="dc.Creator" content="Bang D. Nguyen"><meta name="dc.Creator" content="Laurence Borand"><meta name="dc.Creator" content="Anaïs Domergue"><meta name="dc.Creator" content="Delphine Rapoud"><meta name="dc.Creator" content="Naome Natukunda"><meta name="dc.Creator" content="Sopheak Thai"><meta name="dc.Creator" content="Sylvain Juchet"><meta name="dc.Creator" content="Serge P. Eholié"><meta name="dc.Creator" content="Stephen D. Lawn"><meta name="dc.Creator" content="Serge K. Domoua"><meta name="dc.Creator" content="Xavier Anglaret"><meta name="dc.Creator" content="Didier Laureillard"><meta name="dc.Description" content="In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already severely immunocompromised. Mo..."><meta name="Description" content="In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already severely immunocompromised. Mo..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-06-18"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1910708"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202006183822507"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2009679"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1910708">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1910708">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1910708">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults | NEJM">
        <meta property="og:title" content="Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1910708">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/94fb6c6b-dfef-428c-8e05-4f714dc730df/nejmoa1910708_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/94fb6c6b-dfef-428c-8e05-4f714dc730df/nejmoa1910708_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV),
many HIV-infected adults begin antiretroviral therapy (ART) when they are already
severely immunocompromised. Mo...">
        <meta name="twitter:description" content="In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV),
many HIV-infected adults begin antiretroviral therapy (ART) when they are already
severely immunocompromised. Mo...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2398">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa1910708">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1910708">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa1910708;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;issue:issue:doi\:10.1056/nejm_2020.382.issue-25;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1910708" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1910708" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1910708" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1910708" class="inputDoi"><input type="hidden" value="F.-X. Blanc and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;382:2397-2410" class="inputCitation"><input type="hidden" value="06-17-2020" class="inputEPubDate"><input type="hidden" value="June 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup modal-lg"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d63293d0ae0308-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">François-Xavier</span> <span property="familyName">Blanc</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7644-2188" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-7644-2188</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anani D.</span> <span property="familyName">Badje</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maryline</span> <span property="familyName">Bonnet</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Delphine</span> <span property="familyName">Gabillard</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Eugène</span> <span property="familyName">Messou</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Conrad</span> <span property="familyName">Muzoora</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sovannarith</span> <span property="familyName">Samreth</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+12</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bang D.</span> <span property="familyName">Nguyen</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Laurence</span> <span property="familyName">Borand</span>, <span property="honorificSuffix">Pharm.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anaïs</span> <span property="familyName">Domergue</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Delphine</span> <span property="familyName">Rapoud</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Naome</span> <span property="familyName">Natukunda</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sopheak</span> <span property="familyName">Thai</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sylvain</span> <span property="familyName">Juchet</span>, <span property="honorificSuffix">Pharm.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Serge P.</span> <span property="familyName">Eholié</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Stephen D.</span> <span property="familyName">Lawn</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Serge K.</span> <span property="familyName">Domoua</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xavier</span> <span property="familyName">Anglaret</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Didier</span> <span property="familyName">Laureillard</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-0104-9047" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-0104-9047</a></span></span>, for <span property="author" typeof="Person" role="listitem">the STATIS ANRS 12290 Trial Team<sup><a href="#fn2" role="doc-noteref">†</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-12</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">June 17, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">382</span></span>:<span property="pageStart">2397</span>-<span property="pageEnd">2410</span></div><div class="doi">DOI: 10.1056/NEJMoa1910708</div><div class="core-enumeration"><a href="/toc/nejm/382/25"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">382</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">25</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DFran%25C3%25A7ois-Xavier%2BBlanc%252C%2BAnani%2BD.%2BBadje%252C%2BMaryline%2BBonnet%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D25%26contentID%3D10.1056%252FNEJMoa1910708%26title%3DSystematic%2Bor%2BTest-Guided%2BTreatment%2Bfor%2BTuberculosis%2Bin%2BHIV-Infected%2BAdults%26publicationDate%3D06%252F18%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1910708" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DFran%25C3%25A7ois-Xavier%2BBlanc%252C%2BAnani%2BD.%2BBadje%252C%2BMaryline%2BBonnet%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D25%26contentID%3D10.1056%252FNEJMoa1910708%26title%3DSystematic%2Bor%2BTest-Guided%2BTreatment%2Bfor%2BTuberculosis%2Bin%2BHIV-Infected%2BAdults%26publicationDate%3D06%252F18%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/ef1b03f1-3345-45a9-bfcd-7f9a267a4235/nejmoa1910708.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1910708.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1910708" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1910708" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1910708.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already severely immunocompromised. Mortality after ART initiation is high in these patients, and tuberculosis and invasive bacterial diseases are common causes of death.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph"><a id="exam-tint-three-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="three-d">We conducted a 48-week trial of empirical treatment for tuberculosis as compared with treatment guided by testing in HIV-infected adults who had not previously received ART and had CD4+ T-cell counts below 100 cells per cubic millimeter.</span> Patients recruited in Ivory Coast, Uganda, Cambodia, and Vietnam were randomly assigned in a 1:1 ratio to undergo screening (Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography) to determine whether treatment for tuberculosis should be started or to receive systematic empirical treatment with rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months. The primary end point was a composite of death from any cause or invasive bacterial disease within 24 weeks (primary analysis) or within 48 weeks after randomization.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 522 patients in the systematic-treatment group and 525 in the guided-treatment group were included in the analyses. <a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="two-c two-d">At week 24, the rate of death from any cause or invasive bacterial disease (calculated as the number of first events per 100 patient-years) was 19.4 with systematic treatment and 20.3 with guided treatment (adjusted hazard ratio, 0.95; 95% confidence interval [CI], 0.63 to 1.44). At week 48, the corresponding rates were 12.8 and 13.3 (adjusted hazard ratio, 0.97 [95% CI, 0.67 to 1.40]). At week 24, the probability of tuberculosis was lower with systematic treatment than with guided treatment (3.0% vs. 17.9%; adjusted hazard ratio, 0.15; 95% CI, 0.09 to 0.26), but the probability of grade 3 or 4 drug-related adverse events was higher with systematic treatment (17.4% vs. 7.2%; adjusted hazard ratio 2.57; 95% CI, 1.75 to 3.78).</span> Serious adverse events were more common with systematic treatment.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph"><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="two-d">Among severely immunosuppressed adults with HIV infection who had not previously received ART, systematic treatment for tuberculosis was not superior to test-guided treatment in reducing the rate of death or invasive bacterial disease over 24 or 48 weeks and was associated with more grade 3 or 4 adverse events.</span> (Funded by the Agence Nationale de Recherches sur le Sida et les Hépatites Virales; STATIS ANRS 12290 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02057796" target="_blank">NCT02057796</a>.)</div></section></section><div class="core-digital-object visual-abstract">
<div class="ng-page_separator pt-24"></div>
<div class="ng-do-media">
    <button data-toggle="modal" data-target="#doPopup" class="ng-do-media_btn" modal-size="lg"></button>
    <div data-ajaxurl="/do/10.1056/NEJMdo005793/full/?ajaxRequest=true" class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="#" class="ng-do-media_item-img-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005793" data-multimedia-filename="NEJMdo005793_600x400.jpg">
                <img src="/cms/asset/f27772b3-fd59-431d-9ba1-cb2b3baa006d/media/NEJMdo005793_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-visual"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/visual-abstract" class="ng-do-media_item-type-link">Visual Abstract</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="#" class="ng-do-media_item-title-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005793" data-multimedia-filename="NEJMdo005793_600x400.jpg">Systematic or Test-Guided Treatment for TB in HIV</a>
            </h6>
        </div>
    </div>
</div>

</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Tuberculosis is the 10th leading cause of death worldwide and the main cause of death from a single infectious agent.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-1" href-manipulated="true" aria-label="Reference 1">1</a></sup> In 2019, the World Health Organization (WHO) estimated that 251,000 annual deaths due to tuberculosis occurred in persons with human immunodeficiency virus (HIV) infection.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-2" href-manipulated="true" aria-label="Reference 1">1</a></sup> Coinfection with tuberculosis and HIV still represents a “cursed duet,”<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2" href-manipulated="true" aria-label="Reference 2">2</a></sup> especially in sub-Saharan Africa and Asia.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4-1" href-manipulated="true">3,4</a></sup> The WHO recommends that people living with HIV infection should be systematically screened for active tuberculosis and that those who report current cough, fever, weight loss, or night sweats should be evaluated for tuberculosis and other diseases.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6" id="body-ref-r6" href-manipulated="true">5,6</a></sup> However, because of variations in the appearance of chest radiographs and the decrease in the performance of sputum-smear microscopy as the CD4+ T-cell count declines,<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7" href-manipulated="true" aria-label="Reference 7">7</a></sup> a diagnosis of tuberculosis remains challenging in HIV-infected adults, especially when they are severely immunosuppressed.</div><div role="paragraph">Despite increasing access to antiretroviral therapy (ART) in regions with high burdens of tuberculosis and HIV, many HIV-infected adults still present for care when they are already severely immunocompromised.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9" id="body-ref-r9" href-manipulated="true">8,9</a></sup> Among these adults, mortality after the initiation of ART is high, and tuberculosis and invasive bacterial diseases are common causes of death.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12 r13 r14 r15 r16 r17" id="body-ref-r17" href-manipulated="true">10-17</a></sup> Persons with active tuberculosis may report no or few symptoms. <a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">The use of the urinary lipoarabinomannan (LAM) test and Xpert MTB/RIF test (a rapid nucleic acid amplification test to detect <i>Mycobacterium tuberculosis</i> and resistance to rifampin) increases the chance of correctly diagnosing tuberculosis.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-1" href-manipulated="true" aria-label="Reference 18">18</a></sup> However, physicians commonly initiate empirical treatment for tuberculosis without using these tests.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20" id="body-ref-r20-1" href-manipulated="true">19,20</a></sup> One potential benefit of empirical treatment for tuberculosis is that rifampin is active against several common pathogens that can be fatal in patients with advanced HIV infection. We conducted a randomized, clinical trial to compare the benefits and risks of a tuberculosis-screening strategy involving a combination of investigations (urinary LAM test, Xpert MTB/RIF test, and chest radiography) and targeted treatment with those of a strategy of systematic empirical treatment for tuberculosis in HIV-infected patients with severe immunosuppression.</span></div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">This research was sponsored and funded by the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS). The funding agency had no role in the trial design, the collection and analysis of the data, or the decision to submit the manuscript for publication. The STATIS (Systematic vs. Test-Guided Antituberculosis Treatment Impact in Severely Immuno-suppressed HIV-Infected Adults Initiating Antiretroviral Therapy with CD4 Cell Counts &lt;100/mm<sup>3</sup>) ANRS 12290 trial was a multicenter, randomized, open-label, superiority trial that compared the efficacy of two strategies in reducing mortality and the risk of invasive bacterial diseases among ambulatory HIV-infected adults with no overt evidence of tuberculosis, whose CD4+ T-cell count was less than 100 cells per cubic millimeter, and who were ready to start ART (see Section 1.2 in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org). Patients were recruited between September 29, 2014, and May 3, 2017, in Abidjan, Ivory Coast (two centers); Mbarara, Uganda (two centers); Phnom Penh, Cambodia (one center); and Ho Chi Minh City, Vietnam (one center).</div><div role="paragraph">After written informed consent was obtained, the patients were randomly assigned in a 1:1 ratio to undergo screening to guide treatment for tuberculosis (guided-treatment group) or to receive systematic empirical treatment for tuberculosis (systematic-treatment group). A sequentially numbered block-randomization list was computer-generated and included in a software tool that allowed access to the next available trial identification number and treatment group. Randomization was stratified according to country (Ivory Coast, Uganda, Cambodia, or Vietnam) and baseline CD4+ T-cell count (≤50 cells per cubic millimeter or 51 to 99 cells per cubic millimeter). The trial was conducted in compliance with current international regulations, including the Declaration of Helsinki<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup> and the Good Clinical Practice guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use,<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> and was approved by ethics and regulatory authorities in each country. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the <a href="#ap1">protocol</a>, available at NEJM.org.</div></section><section id="sec-1-2"><h3>Trial Interventions</h3><div role="paragraph">The patients were evaluated by on-site physicians on the day of enrollment and randomization (day 0) and then at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48. Between these visits, the patients were asked to come to the clinic if they had any symptoms or concerns about treatment. On day 0, the patients assigned to the guided-treatment group underwent systematic tuberculosis screening by means of the Xpert MTB/RIF test, the Alere Determine TB LAM Ag urinary test, and chest radiography, regardless of reported symptoms. Only the patients who met the criteria for confirmed or probable tuberculosis, as determined by these tests, started treatment for tuberculosis in this group (see Section 1.4.4 in the <a href="#ap2">Supplementary Appendix</a>). The patients assigned to the systematic-treatment group underwent chest radiography but no other tuberculosis test, even if they reported tuberculosis symptoms; all the patients in this group started treatment for tuberculosis immediately.</div><div role="paragraph">During follow-up, the patients in the guided-treatment group who had not received treatment for tuberculosis were systematically screened for tuberculosis symptoms with the use of the 2010 WHO questionnaire<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-2" href-manipulated="true" aria-label="Reference 5">5</a></sup> at each visit. Those who answered “yes” to any of the four questions or who had any other clinical manifestations suggestive of tuberculosis underwent repeated screening with the Xpert MTB/RIF test, the urinary LAM test, and chest radiography, as well as any other appropriate symptom-driven investigation. Treatment for tuberculosis was initiated in the case of confirmed, probable, or possible tuberculosis. In the systematic-treatment group, patients whose condition had deteriorated before week 24 underwent symptom-driven investigations, including tuberculosis tests when immune reconstitution inflammatory syndrome (IRIS), drug resistance, or poor adherence was suspected. After week 24, the patients in the systematic-treatment group were screened for tuberculosis with the use of the same procedures that were used in the guided-treatment group.</div><div role="paragraph">In both groups, treatment for tuberculosis consisted of a daily oral regimen of isoniazid, rifampin, ethambutol, and pyrazinamide in doses recommended by the WHO, as summarized in the <a href="#ap1">protocol</a>, for 2 months, followed by daily administration of isoniazid and rifampin for 4 months. All the patients received counseling regarding adherence and were offered prophylaxis with trimethoprim–sulfamethoxazole. ART consisted of efavirenz, plus lamivudine or emtricitabine, plus tenofovir or zidovudine, in accordance with the national guidelines from each country. In the guided-treatment group, ART was initiated immediately after randomization in the patients who did not receive a diagnosis of tuberculosis and 2 weeks later in the patients who did. In the systematic-treatment group, all the patients started ART 2 weeks after randomization.</div></section><section id="sec-1-3"><h3>Trial End Points</h3><div role="paragraph">The primary end point was a composite of death from any cause or invasive bacterial disease within 24 weeks (primary analysis) or within 48 weeks (secondary analysis) after randomization. Invasive bacterial disease was defined as a bacteremia or clinical, biologic, or radiologic signs compatible with a bacterial infection of any solid organ or sterile space (standardized definitions of probable and confirmed invasive bacterial diseases are provided in Section 1.4.4.2 in the <a href="#ap2">Supplementary Appendix</a>). Secondary end points included death from any cause; serious adverse events (defined as invasive bacterial diseases, incident tuberculosis, other acquired immunodeficiency syndrome [AIDS]–defining diseases, and other grade 3 or 4 adverse events, as classified according to the Division of AIDS)<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-1" href-manipulated="true" aria-label="Reference 23">23</a></sup>; IRIS<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup>; HIV-1 virologic suppression success (defined as a viral load of &lt;50 copies per milliliter); change in CD4+ T-cell count from baseline; and adherence to treatment. These end points were classified according to standardized criteria (see Section 1.4 in the <a href="#ap2">Supplementary Appendix</a>) and were assessed at 24 and 48 weeks.</div><div role="paragraph">Adherence to ART was assessed by calculating the medication possession ratio (the number of daily doses of antiretroviral drugs dispensed by the pharmacy to each patient, divided by that patient’s total follow-up time in days since the initiation of ART). Adherence to antituberculous drugs was assessed according to the patient’s recall of the number of pills missed over the previous 4 days. All primary and secondary clinical end points were reviewed by two event-documentation committees, one at the trial center level and one at the international level. Members of the committees were aware of the treatment-group assignments.</div></section><section id="sec-1-4"><h3>Statistical Analysis</h3><div role="paragraph">We estimated that the risk of death or invasive bacterial disease in the guided-treatment group would be 14% at 24 weeks.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-2" href-manipulated="true" aria-label="Reference 4">4</a></sup> A sample size of 1050 patients was estimated to provide the trial with 80% power to show a 40% lower risk of death or invasive bacterial disease in the systematic-treatment group than in the guided-treatment group, with a two-sided type I error rate of 5% and a 4.5% loss to follow-up.</div><div role="paragraph">The main analyses of the primary and secondary end points were performed at week 24 on an intention-to-treat basis. The same analyses were performed at week 48 (end of the trial). We used the Kaplan–Meier method to estimate the cumulative probability of the occurrence of an event. Follow-up data were censored when patients were lost to follow-up. Multivariate Cox proportional-hazards models were used to compare the treatment groups with respect to event rates, with adjustment for country and baseline CD4+ T-cell count category. The proportional-hazards assumption was examined. All the patients who underwent randomization were included in the analysis, including the patients who died, were lost to follow-up, or withdrew from the trial. Patients who did not attend the last scheduled visit at 48 weeks, who were not known to have died, and who could not be found after intensive tracing were considered lost to follow-up. There was no imputation for missing data. Because the 95% confidence intervals of the between-group differences with respect to the secondary end points have not been adjusted for multiple comparisons, inferences cannot be made from the results.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Characteristics of the Patients</h3><div role="paragraph">A total of 1050 patients were randomly assigned to a treatment group. Three patients were excluded from the analysis because they had previously received ART (<a href="#f1">Figure 1</a>). Data were obtained from 525 patients in the guided-treatment group and 522 patients in the systematic-treatment group (<a href="#t1">Table 1</a>). The median age of the patients was 35 years (interquartile range, 29 to 41), 436 (41.6%) were women, and the median CD4+ T-cell count was 30 cells per cubic millimeter (interquartile range, 12 to 56). At the time of enrollment, 94.7% of the patients had a Karnofsky performance-status score of at least 80 (on a scale from 0 to 100, with lower scores indicating greater disability), and 354 patients (67.4%) in the guided-treatment group and 346 (66.3%) in the systematic-treatment group reported no symptoms or one tuberculosis symptom. A total of 886 patient-years of follow-up (444 in the guided-treatment group and 442 in the systematic-treatment group) were completed. <a id="exam-tint-three-b"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="three-b">At trial termination, 24 patients (2.3%) were lost to follow-up (11 patients in the guided-treatment group and 13 patients in the systematic-treatment group).</span> The percentage of patients who attended the scheduled trial visits through week 24 was 96.7%, and 95.3% attended the scheduled trial visits through week 48; the percentages in the two treatment groups did not differ meaningfully (Table S1 in the <a href="#ap2">Supplementary Appendix</a>). A total of 521 of 522 patients (99.8%) in the systematic-treatment group started treatment for tuberculosis, of whom 497 (95.4%) completed the 6-month treatment period (<a href="#t1">Table 1</a>). In this group, the percentage of patients who reported having missed at least one antituberculous pill during the 4 days preceding a trial visit varied between 1% and 2% during follow-up (Fig. S4).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1910708_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1910708_f1.jpg"><img src="/cms/10.1056/NEJMoa1910708/asset/94fb6c6b-dfef-428c-8e05-4f714dc730df/assets/images/large/nejmoa1910708_f1.jpg" height="2398" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">The patients assigned to the guided-treatment group underwent tuberculosis screening by means of the Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography to determine whether treatment for tuberculosis should be implemented, and the patients assigned to the systematic-treatment group received empirical treatment for tuberculosis with the World Health Organization–recommended regimen of rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months. ALT denotes alanine aminotransferase, ART antiretroviral therapy, AST aspartate aminotransferase, and ULN upper limit of the normal range.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t1.jpg"><img src="/cms/10.1056/NEJMoa1910708/asset/a1012336-f842-44e3-828b-167ef4fe914e/assets/images/large/nejmoa1910708_t1.jpg" height="3438" width="1572" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">Characteristic</th><th class="xxxx-borders">Guided Treatment<br>(N=525)</th><th class="xxxx-borders">Systematic Treatment <br>(N=522)</th></tr></thead><tbody><tr data-type="row"><td class="xxxx-borders hanging03 shading"><b>Baseline</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">221 (42.0)</td><td class="xxxx-borders">215 (41.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Median age (IQR) — yr</td><td class="xxxx-borders shading">35 (29–41)</td><td class="xxxx-borders shading">35 (29–41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Median body-mass index (IQR)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">19.6 (17.9–21.9)</td><td class="xxxx-borders">19.7 (17.8–21.9)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Karnofsky performance-status score — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">&lt;80</td><td class="xxxx-borders">27 (5.1)</td><td class="xxxx-borders">27 (5.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">≥80</td><td class="xxxx-borders shading">497 (94.7)</td><td class="xxxx-borders shading">494 (94.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Missing data</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">1 (0.2)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">WHO clinical stage — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Stage 1</td><td class="xxxx-borders">152 (29.0)</td><td class="xxxx-borders">146 (28.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">Stage 2</td><td class="xxxx-borders shading">132 (25.1)</td><td class="xxxx-borders shading">148 (28.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Stage &gt;2</td><td class="xxxx-borders">240 (45.7)</td><td class="xxxx-borders">227 (43.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">Missing data</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">1 (0.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Median CD4+ T-cell count (IQR) — cells/mm<sup>3</sup></td><td class="xxxx-borders">28 (12–56)</td><td class="xxxx-borders">32 (13–55)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">CD4+ T-cell count — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">≤50/mm<sup>3</sup></td><td class="xxxx-borders">370 (70.5)</td><td class="xxxx-borders">370 (70.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">51–99/mm<sup>3</sup></td><td class="xxxx-borders shading">155 (29.5)</td><td class="xxxx-borders shading">152 (29.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Median plasma HIV-1 RNA level (IQR) — log<sub>10</sub> copies/ml</td><td class="xxxx-borders">5.5 (5.2–5.8)</td><td class="xxxx-borders">5.4 (5.1–5.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Median hemoglobin level — g/dl</td><td class="xxxx-borders shading">11.5 (9.9–13.4)</td><td class="xxxx-borders shading">11.7 (9.9–13.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Positive plasma HBV surface antigen — no. (%)</td><td class="xxxx-borders">47 (9.0)</td><td class="xxxx-borders">48 (9.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Positive plasma HCV antibodies — no. (%)</td><td class="xxxx-borders shading">36 (6.9)</td><td class="xxxx-borders shading">35 (6.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Plasma ALT &gt;2.5× ULN — no. (%)</td><td class="xxxx-borders">49 (9.3)</td><td class="xxxx-borders">36 (6.9)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Patients with tuberculosis symptoms according to WHO criteria — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">No symptoms</td><td class="xxxx-borders">199 (37.9)</td><td class="xxxx-borders">196 (37.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">1 Symptom</td><td class="xxxx-borders shading">155 (29.5)</td><td class="xxxx-borders shading">150 (28.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">2 Symptoms</td><td class="xxxx-borders">90 (17.1)</td><td class="xxxx-borders">103 (19.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">3 Symptoms</td><td class="xxxx-borders shading">62 (11.8)</td><td class="xxxx-borders shading">58 (11.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">4 Symptoms</td><td class="xxxx-borders">18 (3.4)</td><td class="xxxx-borders">15 (2.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">Missing data</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">0</td></tr><tr data-type="row"><td class="xxxx-borders hanging03"><b>Follow-up</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Lost to follow-up — no. (%)</td><td class="xxxx-borders shading">11 (2.1)</td><td class="xxxx-borders shading">13 (2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Follow-up time — person-yr</td><td class="xxxx-borders">444</td><td class="xxxx-borders">442</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Initiated ART — no. (%)</td><td class="xxxx-borders shading">523 (99.6)</td><td class="xxxx-borders shading">510 (97.7)</td></tr><tr data-type="row"><td class="xxxx-borders hanging13">First-line regimen</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Tenofovir+lamivudine or emtricitabine+efavirenz</td><td class="xxxx-borders shading">490 (93.7)</td><td class="xxxx-borders shading">473 (92.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Zidovudine+lamivudine+efavirenz</td><td class="xxxx-borders">32 (6.1)</td><td class="xxxx-borders">35 (6.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Other<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">2 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Medication possession ratio &gt;95%<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">445 (85.1)</td><td class="xxxx-borders">434 (85.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Initiated treatment for tuberculosis — no. (%)</td><td class="xxxx-borders shading">93 (17.7)</td><td class="xxxx-borders shading">521 (99.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Completed 6 mo of treatment</td><td class="xxxx-borders">85 (91.4)</td><td class="xxxx-borders">497 (95.4)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Chest radiography performed — no. of patients/no. of tests</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">At day 0</td><td class="xxxx-borders">519/519</td><td class="xxxx-borders">514/516</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">After day 0 and before wk 24</td><td class="xxxx-borders shading">192/313</td><td class="xxxx-borders shading">488/870</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">After wk 24</td><td class="xxxx-borders">81/108</td><td class="xxxx-borders">156/180</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Urinary LAM test performed — no. of patients/no. of tests</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">At day 0</td><td class="xxxx-borders">524/524</td><td class="xxxx-borders">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">After day 0 and before wk 24</td><td class="xxxx-borders shading">146/183</td><td class="xxxx-borders shading">24/26</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">After wk 24</td><td class="xxxx-borders">43/54</td><td class="xxxx-borders">14/17</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Xpert MTB/RIF test performed on sputum sample — no. of patients/no. of tests</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">At day 0</td><td class="xxxx-borders">472/475</td><td class="xxxx-borders">0/0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">After day 0 and before wk 24</td><td class="xxxx-borders shading">154/227</td><td class="xxxx-borders shading">37/49</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">After wk 24</td><td class="xxxx-borders">51/70</td><td class="xxxx-borders">19/30</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Patients at Baseline and during Follow-up.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">None of the baseline characteristics differed significantly between strategies. Percentages may not total 100 because of rounding. ALT denotes alanine aminotransferase, ART antiretroviral therapy, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, IQR interquartile range, LAM lipoarabinomannan, ULN upper limit of the normal range, and WHO World Health Organization.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Tuberculosis symptoms according to the WHO criteria<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-3" href-manipulated="true" aria-label="Reference 5">5</a></sup> include cough, fever, weight loss, and night sweats.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">All 3 patients received tenofovir, lamivudine, and lopinavir–ritonavir.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">The medication possession ratio is the number of daily doses of antiretroviral drugs dispensed by the pharmacy to each patient, divided by that patient’s total follow-up time in days since the initiation of ART.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Clinical End Points</h3><div role="paragraph">During follow-up, 90 patients died (69 before week 24) (Tables S16 and S17), and 42 cases of invasive bacterial disease occurred in 41 patients (34 cases occurred in 33 patients before week 24) (Table S18). The cases of invasive bacterial disease included 13 cases of bacteremia, 12 cases of pneumonia, 6 cases of severe sepsis, 5 cases of pyelonephritis, 2 cases of necrotizing fasciitis, 1 case of salpingitis, 1 cases of skin abscess, 1 case of bacterial enteritis, and 1 case of appendicitis. The proportional-hazards assumption was fulfilled. With respect to the primary outcome, the rate of death from any cause or invasive bacterial disease (calculated as the number of first events per 100 patient-years) was 19.4 in the systematic-treatment group and 20.3 in the guided-treatment group at week 24 (adjusted hazard ratio, 0.95; 95% confidence interval [CI], 0.63 to 1.44) (<a href="#t2">Table 2</a> and <a href="#f2">Figure 2</a>). The most common causes of death were tuberculosis (17 patients in the guided-treatment group and 4 in the systematic-treatment group), invasive bacterial disease (3 patients and 6 patients, respectively), and AIDS-defining illnesses (7 patients in each group). Six deaths in the guided-treatment group and 15 deaths in the systematic-treatment group were of unknown cause (Table S19).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1910708_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1910708_f2.jpg"><img src="/cms/10.1056/NEJMoa1910708/asset/4530e058-0710-49d6-8031-55ae84941e63/assets/images/large/nejmoa1910708_f2.jpg" height="3438" width="2255" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Analysis of the Primary Composite End Point and End-Point Components.</div><div class="notes"><div role="doc-footnote">Shown are the Kaplan–Meier curves for the probability of the primary composite end point of death from any cause or invasive bacterial disease (Panel A) and the probability of the end-point components of death from any cause (Panel B) and invasive bacterial disease (defined as a bacteremia or clinical, biologic, or radiologic signs compatible with a bacterial infection of any solid organ or sterile space). In each panel, the inset shows the same data on an enlarged y axis. 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t2.jpg"><img src="/cms/10.1056/NEJMoa1910708/asset/0f8bef57-f563-4c8c-b877-b11c1d4f5d2b/assets/images/large/nejmoa1910708_t2.jpg" height="1968" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Clinical End Points</th><th class="txxx-borders" colspan="2"><span>Guided Treatment</span></th><th class="txxx-borders" colspan="2"><span>Systematic Treatment</span></th><th class="txxr-borders">Adjusted Hazard<br>Ratio (95% CI)<a href="#t2fn2" role="doc-noteref">†</a></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">No. of First Events</th><th class="xxxx-borders">Rate<br>(95% CI)<a href="#t2fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">No. of First Events</th><th class="xxxx-borders">Rate<br>(95% CI)<a href="#t2fn3" role="doc-noteref">‡</a></th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Primary end point at 24 wk: composite of death from any cause or invasive bacterial disease</td><td class="xxxx-borders shading">46</td><td class="xxxx-borders shading">20.3 (14.5–26.2)</td><td class="xxxx-borders shading">44</td><td class="xxxx-borders shading">19.4 (13.7–25.1)</td><td class="xxxr-borders shading">0.95 (0.63–1.44)<a href="#t2fn4" role="doc-noteref">§</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Secondary end points at 24 wk<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Death from any cause</td><td class="xxxx-borders shading">36</td><td class="xxxx-borders shading">15.6 (10.5–20.8)</td><td class="xxxx-borders shading">33</td><td class="xxxx-borders shading">14.4 (9.5–19.3)</td><td class="xxxr-borders shading">0.92 (0.57–1.47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Invasive bacterial disease</td><td class="xxxx-borders">15</td><td class="xxxx-borders">6.7 (3.7–11.0)</td><td class="xxxx-borders">18</td><td class="xxxx-borders">8.0 (4.7–12.6)</td><td class="xxxr-borders">1.19 (0.60–2.36)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Tuberculosis<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">93</td><td class="xxxx-borders shading">47.2 (37.6–56.8)</td><td class="xxxx-borders shading">15</td><td class="xxxx-borders shading">6.7 (3.7–11.0)</td><td class="xxxr-borders shading">0.15 (0.09–0.26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">IRIS</td><td class="xxxx-borders">57</td><td class="xxxx-borders">26.8 (19.8–33.7)</td><td class="xxxx-borders">17</td><td class="xxxx-borders">7.6 (4.4–12.1)</td><td class="xxxr-borders">0.39 (0.22–0.69)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">AIDS-defining events</td><td class="xxxx-borders shading">62</td><td class="xxxx-borders shading">29.3 (22.0–36.5)</td><td class="xxxx-borders shading">46</td><td class="xxxx-borders shading">21.3 (15.1–27.5)</td><td class="xxxr-borders shading">0.73 (0.50–1.06)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Grade 3 or 4 adverse events<a href="#t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">125</td><td class="xxxx-borders">65.5 (54.0–76.9)</td><td class="xxxx-borders">166</td><td class="xxxx-borders">94.3 (80.0–108.7)</td><td class="xxxr-borders">1.39 (1.11–1.76)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Grade 3 or 4 drug-related adverse events<a href="#t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">37</td><td class="xxxx-borders shading">16.9 (11.5–22.3)</td><td class="xxxx-borders shading">89</td><td class="xxxx-borders shading">44.7 (35.4–54.0)</td><td class="xxxr-borders shading">2.57 (1.75–3.78)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Secondary end points at 48 wk<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Composite of death from any cause or invasive bacterial disease</td><td class="xxxx-borders shading">58</td><td class="xxxx-borders shading">13.3 (9.9–16.7)</td><td class="xxxx-borders shading">56</td><td class="xxxx-borders shading">12.8 (9.5–16.2)</td><td class="xxxr-borders shading">0.97 (0.67–1.40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Death from any cause</td><td class="xxxx-borders">45</td><td class="xxxx-borders">10.1 (7.4–13.5)</td><td class="xxxx-borders">45</td><td class="xxxx-borders">10.2 (7.4–13.6)</td><td class="xxxr-borders">1.01 (0.67–1.52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Invasive bacterial disease</td><td class="xxxx-borders shading">19</td><td class="xxxx-borders shading">4.4 (2.7–6.9)</td><td class="xxxx-borders shading">22</td><td class="xxxx-borders shading">5.1 (3.2–7.7)</td><td class="xxxr-borders shading">1.15 (0.62–2.13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Tuberculosis<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">99</td><td class="xxxx-borders">26.2 (21.0–31.3)</td><td class="xxxx-borders">18</td><td class="xxxx-borders">4.2 (2.5–6.6)</td><td class="xxxr-borders">0.17 (0.10–0.28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">IRIS</td><td class="xxxx-borders shading">59</td><td class="xxxx-borders shading">14.4 (10.7–18.1)</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">3.9 (2.3–6.3)</td><td class="xxxr-borders shading">0.27 (0.16–0.47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">AIDS-defining events</td><td class="xxxx-borders">72</td><td class="xxxx-borders">17.7 (13.6–21.8)</td><td class="xxxx-borders">52</td><td class="xxxx-borders">12.6 (9.2–16.0)</td><td class="xxxr-borders">0.71 (0.49–1.01)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Grade 3 or 4 adverse events<a href="#t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">143</td><td class="xxxx-borders shading">39.8 (33.3–46.4)</td><td class="xxxx-borders shading">179</td><td class="xxxx-borders shading">54.7 (46.7–62.8)</td><td class="xxxr-borders shading">1.32 (1.06–1.65)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Grade 3 or 4 drug-related adverse events<a href="#t2fn7" role="doc-noteref">**</a></td><td class="xbxx-borders">39</td><td class="xbxx-borders">9.3 (6.4–12.2)</td><td class="xbxx-borders">94</td><td class="xbxx-borders">24.9 (19.9–30.0)</td><td class="xbxr-borders">2.59 (1.78–3.76)</td></tr></tbody></table></div><figcaption><div class="caption">Clinical End Points at 24 and 48 Weeks.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">AIDS denotes acquired immunodeficiency syndrome, and IRIS immune reconstitution inflammatory syndrome.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The hazard ratios are for the systematic-treatment group as compared with the guided-treatment group and were adjusted for country (Ivory Coast, Uganda, Cambodia, or Vietnam) and baseline CD4+ T-cell count (≤50 per cubic millimeter or 51 to 99 per cubic millimeter).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Rate was calculated as the number of first events per 100 patient-years.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">P=0.82.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">Because the trial protocol did not include a plan for adjustment for multiple comparisons, the results of the analyses of secondary end points are reported with point estimates and 95% confidence intervals, without P values, and the results cannot be used to infer effects.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">The end point of tuberculosis includes prevalent and incident cases. Of the 117 cases of tuberculosis, 54 included pulmonary involvement only, 18 included pulmonary and extra pulmonary involvement, and 45 included extrapulmonary involvement only.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t2fn7" role="paragraph">Adverse events were graded according to the criteria of the Division of AIDS.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-2" href-manipulated="true" aria-label="Reference 23">23</a></sup></div></div></div></figcaption></figure></div><div role="paragraph">Overall, tuberculosis occurred in 117 patients (99 patients in the guided-treatment group and 18 patients in the systematic-treatment group), but this total includes 50 prevalent cases of tuberculosis that were diagnosed at baseline (49 cases in the guided-treatment group, including 3 cases of rifampin-resistant tuberculosis, according to Xpert MTB/RIF testing) and 67 cases of incident tuberculosis (50 cases in the guided-treatment group and 17 cases in the systematic-treatment group). Among the 199 patients (37.9%) in the guided-treatment group who reported no tuberculosis symptoms at baseline, 10 (5.0%) received a diagnosis of prevalent tuberculosis. In the guided-treatment group, 29 cases of incident tuberculosis occurred before week 4, 9 cases between week 4 and week 8, 1 case between week 8 and week 12, 5 cases between week 12 and week 24, and 6 cases between week 24 and week 48. The 1 case of prevalent tuberculosis in the systematic-treatment group was documented according to a positive urinary LAM test that was incorrectly performed at enrollment. The 17 cases of incident tuberculosis in the systematic-treatment group included 11 cases of paradoxical tuberculosis-associated IRIS that occurred 3 to 70 days after the initiation of ART, 3 cases of tuberculosis that were diagnosed before week 24 (including 1 that occurred before the initiation of ART and 2 that occurred after an untimely discontinuation of treatment for tuberculosis 2 months after enrollment), and 3 cases that were diagnosed after week 24. All strains of <i>M. tuberculosis</i> that were isolated in the systematic-treatment group were fully susceptible to antituberculosis drugs. The cumulative probability of receiving a diagnosis of incident or prevalent tuberculosis was 3.0% in the systematic-treatment group and 17.9% in the guided-treatment group at week 24 (adjusted hazard ratio, 0.15; 95% CI, 0.09 to 0.26) and 3.6% and 19.2%, respectively, at week 48 (adjusted hazard ratio, 0.17; 95% CI, 0.10 to 0.28).</div></section><section id="sec-2-3"><h3>ART, Virologic Response, and Immune Reconstitution</h3><div role="paragraph">In the guided-treatment group, ART was initiated in 523 patients (99.6%): 477 (91.2%) started ART during the first week of the trial, and 40 (7.6%) started ART during the second week. In the systematic-treatment group, ART was initiated in 510 patients (97.7%): 447 (87.6%) started ART at week 2, and 32 (6.3%) started ART between week 2 and week 4. The ART medication possession ratio did not differ significantly between the two treatment groups (<a href="#t1">Table 1</a>). The HIV viral load was below 50 copies per milliliter in 576 of the 935 patients (61.6%) with available data on viral load at week 24 (298 of 466 patients [63.9%] in the guided-treatment group and 278 of 469 patients [59.3%] in the systematic-treatment group) and in 646 of the 885 patients (73.0%) with available data on viral load at week 48 (324 of 446 patients [72.6%] in the guided-treatment group and 322 of 439 patients [73.3%] in the systematic-treatment group). The median gain in the CD4+ T-cell count was 94 cells per cubic millimeter (interquartile range, 51 to 147) at week 24 (105 cells per cubic millimeter in the guided-treatment group and 86 cells per cubic millimeter in the systematic-treatment group) and 140 cells per cubic millimeter (interquartile range, 91 to 207) at week 48 (147 cells per cubic millimeter and 133 cells per cubic millimeter in the two groups, respectively).</div></section><section id="sec-2-4"><h3>Adverse Events</h3><div role="paragraph">Overall, 495 serious adverse events (220 in the guided-treatment group and 275 in the systematic-treatment group) occurred in 322 patients (143 in the guided-treatment group and 179 in the systematic-treatment group), including 150 grade 3 or 4 drug-related adverse events (45 in the guided-treatment group and 105 in the systematic-treatment group) in 133 patients (39 in the guided-treatment group and 94 in the systematic-treatment group) (<a href="#t3">Table 3</a>). The cumulative 24-week probability of grade 3 or 4 drug-related adverse events was 17.4% in the systematic-treatment group and 7.2% in the guided-treatment group (adjusted hazard ratio, 2.57; 95% CI, 1.75 to 3.78). Treatment for tuberculosis was stopped prematurely in 24 patients (4.6%) in the systematic-treatment group owing to adverse events. During follow-up, 79 cases of IRIS (59 in the guided-treatment group and 20 in the systematic-treatment group) occurred in 76 patients (59 in the guided-treatment group and 17 in the systematic-treatment group), including 60 cases of tuberculosis-associated IRIS (49 cases and 11 cases in the two groups, respectively).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t3.jpg"><img src="/cms/10.1056/NEJMoa1910708/asset/6f403040-8ff5-45be-ba37-d52546370c5d/assets/images/large/nejmoa1910708_t3.jpg" height="3088" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Serious Adverse Event</th><th class="txxx-borders" colspan="2"><span>All Events<br>(495 Events)<a href="#t3fn1" role="doc-noteref">*</a></span></th><th class="txxr-borders" colspan="2"><span>Drug-Related Events<br>(150 Events)<a href="#t3fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Guided<br>Treatment</th><th class="xxxx-borders">Systematic<br>Treatment</th><th class="xxxx-borders">Guided<br>Treatment</th><th class="xxxr-borders">Systematic<br>Treatment</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of events</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Invasive bacterial infections</td><td class="xxxx-borders shading">20</td><td class="xxxx-borders shading">22</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Isolated bacteremia</td><td class="xxxx-borders">4</td><td class="xxxx-borders">9</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Bacterial pneumonia</td><td class="xxxx-borders shading">8</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Severe sepsis</td><td class="xxxx-borders">2</td><td class="xxxx-borders">4</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pyelonephritis</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Necrotizing fasciitis</td><td class="xxxx-borders">2</td><td class="xxxx-borders">0</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Bacterial enteritis</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Salpingitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Skin abscess</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Appendicitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Incident tuberculosis<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">50</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Other AIDS-defining illnesses</td><td class="xxxx-borders">31</td><td class="xxxx-borders">39</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cryptococcosis</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">10</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nontuberculous mycobacteriosis</td><td class="xxxx-borders">5</td><td class="xxxx-borders">2</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pneumocystis pneumonia</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Esophageal candidiasis</td><td class="xxxx-borders">3</td><td class="xxxx-borders">8</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cytomegalovirus retinitis</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Isosporiasis</td><td class="xxxx-borders">2</td><td class="xxxx-borders">2</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cryptosporidiosis</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Microsporidiosis</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Progressive multifocal leukoencephalopathy</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Kaposi’s sarcoma</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Solid tumors other than Kaposi’s sarcoma</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Wasting syndrome</td><td class="xxxx-borders">3</td><td class="xxxx-borders">4</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Other grade 3 or 4 adverse events</td><td class="xxxx-borders shading">119</td><td class="xxxx-borders shading">197</td><td class="xxxx-borders shading">45</td><td class="xxxr-borders shading">105</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Noninfectious transaminitis</td><td class="xxxx-borders">26</td><td class="xxxx-borders">43</td><td class="xxxx-borders">17</td><td class="xxxr-borders">39</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pruritus, rash, mucous ulcerations</td><td class="xxxx-borders shading">8</td><td class="xxxx-borders shading">35</td><td class="xxxx-borders shading">8</td><td class="xxxr-borders shading">34</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stevens–Johnson syndrome</td><td class="xxxx-borders">2</td><td class="xxxx-borders">3</td><td class="xxxx-borders">2</td><td class="xxxr-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Neutropenia</td><td class="xxxx-borders shading">16</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">5</td><td class="xxxr-borders shading">10</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Anemia</td><td class="xxxx-borders">7</td><td class="xxxx-borders">14</td><td class="xxxx-borders">1</td><td class="xxxr-borders">4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Thrombopenia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Bicytopenia or pancytopenia</td><td class="xxxx-borders">6</td><td class="xxxx-borders">3</td><td class="xxxx-borders">2</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Neuropsychiatric disorders</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">4</td><td class="xxxr-borders shading">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nonspecific acute fever</td><td class="xxxx-borders">5</td><td class="xxxx-borders">13</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonspecific kidney failure</td><td class="xxxx-borders shading">7</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">5</td><td class="xxxr-borders shading">4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2</td><td class="xxxx-borders">0</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hyperuricemia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gynecomastia</td><td class="xxxx-borders">1</td><td class="xxxx-borders">2</td><td class="xxxx-borders">1</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">36</td><td class="xxxx-borders shading">50</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Total</td><td class="xbxx-borders">220</td><td class="xbxx-borders">275</td><td class="xbxx-borders">45</td><td class="xbxr-borders">105</td></tr></tbody></table></div><figcaption><div class="caption">Distribution of Serious Adverse Events According to Treatment Group.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">During follow-up, 495 serious adverse events occurred in 322 patients. Serious adverse events were defined as invasive bacterial diseases, incident tuberculosis, other AIDS-defining diseases, and other grade 3 or 4 events (classified according to the Division of AIDS<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-3" href-manipulated="true" aria-label="Reference 23">23</a></sup>).</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">The 150 serious drug-related adverse events are included with the 495 serious adverse events. Drug-relatedness was first assessed by an adjudication committee at the national level and was then reviewed by an international adjudication committee. The two committees were aware of the treatment-group assignments. A dash indicates that an event cannot be caused by medications.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">Overall, 117 patients had tuberculosis: 50 cases were diagnosed at baseline (prevalent tuberculosis) and 67 were diagnosed during follow-up as new cases (incident tuberculosis). Only the 67 incident cases are shown in this table.</div></div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">The results of the STATIS trial showed that among severely immunosuppressed adults who had not previously received ART, systematic empirical treatment for tuberculosis was not superior to a strategy involving a combination of repeated tuberculosis screening and targeted treatment for tuberculosis. Both strategies were associated with a lower-than-expected rate of death or invasive bacterial disease at week 24, as compared with previous trials and studies. The initial systematic tuberculosis-screening strategy used at enrollment captured a high number of prevalent tuberculosis diagnoses among asymptomatic patients or those with few symptoms, and additional symptom-driven screening allowed early detection of incident tuberculosis after ART was initiated.</div><div role="paragraph">Empirical treatment for tuberculosis has accounted for up to 15% of instances in which treatment has been initiated in some health care settings.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20-2" href-manipulated="true" aria-label="Reference 20">20</a></sup> Empirical treatment has been compared with isoniazid preventive therapy in one trial involving outpatients, which did not show a reduction in mortality at 6 months.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup> An open cluster-randomized trial also did not show a reduction in mortality or the risk of hospitalization at 6 months.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> Another trial of empirical treatment for tuberculosis was stopped prematurely because of slow recruitment.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27" href-manipulated="true" aria-label="Reference 27">27</a></sup> In the current trial, systematic treatment for tuberculosis was associated with a higher probability of grade 3 or 4 drug-related toxic effects than test-guided treatment, although treatment had to be stopped in only 4.6% of the patients in the systematic-treatment group because of adverse reactions. Although such drug-related toxic effects are nonfatal, they might lead physicians to avoid systematic treatment for tuberculosis if they have access to Xpert MTB/RIF and urinary LAM tests.</div><div role="paragraph">Our tuberculosis-screening strategy was used to detect prevalent tuberculosis, regardless of symptoms. At the time of screening, 5% of the asymptomatic patients received a diagnosis of tuberculosis. After the initiation of ART, in order to capture incident tuberculosis, these tests were repeated when the results of the WHO tuberculosis symptoms questionnaire<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-4" href-manipulated="true" aria-label="Reference 5">5</a></sup> were positive. This continuous strategy was a compromise between current practice and the repeated use of simple tests that are not yet routinely used in this context, although their usefulness in detecting tuberculosis in patients with advanced immunodeficiency has been shown.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-2" href-manipulated="true" aria-label="Reference 18">18</a></sup> The use of this repeated-testing strategy identified 93 cases of tuberculosis in 525 patients (17.7%) at week 24, with the majority of patients receiving a diagnosis within the first 4 weeks — a rate similar to that in previous studies<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28 r29 r30" id="body-ref-r30" href-manipulated="true">28-30</a></sup> and probably reflecting the level of background tuberculosis in this population. In the population targeted by the trial, invasive bacterial diseases are important causes of death.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31" id="body-ref-r31" href-manipulated="true" aria-label="Reference 31">31</a></sup> When designing the composite primary end point, we speculated that 6 months of rifampin therapy could help to prevent some bacterial-associated illnesses. Although we cannot rule out a potential underestimation of invasive bacterial diseases in both treatment groups, our results suggest that treatment for tuberculosis did not have a detectable effect on the rate of invasive bacterial diseases.</div><div role="paragraph"><a id="exam-tint-three-a"></a><a id="exam-tint-three-c"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-c">This trial has several limitations. First, neither of the assigned strategies can be directly compared with those used in current practice. At the time the trial was designed, most clinicians used only sputum smear for tuberculosis screening before initiating ART, but we anticipated that the development of the Xpert MTB/RIF and urinary LAM tests would lead to their use in future care. Second, although isoniazid preventive therapy was known to decrease the rate of, and mortality from, tuberculosis among HIV-infected adults living in areas with a high burden of tuberculosis,<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32" href-manipulated="true" aria-label="Reference 32">32</a></sup> at the time of randomization, isoniazid preventive therapy was deliberately not given to the patients who were assigned to the guided-treatment group to avoid the potential risk of treating undiagnosed tuberculosis with isoniazid alone. Because the patients were regularly screened for tuberculosis at each trial visit, we considered that this strategy was acceptable during the 48 weeks of the trial.</span> After completion of the trial, isoniazid preventive therapy was considered in accordance with the national tuberculosis policy at each trial site. Third, despite systematic review, causes of death remained undocumented in 21 patients (23%), particularly among the patients who died in the systematic-treatment group (15 of 45 patients). Unknown causes of death are common in such trials, even at trial sites that are familiar with clinical research involving patients who are coinfected with tuberculosis and HIV.<sup><a href="#core-r33" role="doc-biblioref" data-xml-rid="r33 r34 r35 r36" id="body-ref-r36" href-manipulated="true">33-36</a></sup></div><div role="paragraph">In conclusion, systematic empirical treatment for tuberculosis and treatment guided by specific testing had similar effects on the rate of death or invasive bacterial disease in a population of HIV-infected adults with CD4+ T-cell counts below 100 cells per cubic millimeter.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by the <span class="named-content" data-type="funder">Agence Nationale de Recherches sur le Sida et les Hépatites Virales</span> (ANRS, grant 12290).</div><div role="paragraph">No potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients for their participation in the trial; the staff at the national tuberculosis and HIV/AIDS programs in Cambodia, Ivory Coast, Uganda, and Vietnam for their support and help in making this trial possible; Claire Rekacewicz, Nicolas Rouveau, Pauline Justumus, Noémie Mercier, Paula Garcia, and Alpha Diallo for their active support at the ANRS headquarters; Christine Danel for early discussions about the design of the trial; Allé Baba Dieng for his active role in implementing the trial; Andrew Ramsay, Célestin Mangoua, Laurence Weiss, and François Raffi (members of the trial scientific advisory board, chaired by Anthony D. Harries) for their important contributions to the trial; Philippe Flandre, Tom Harrison, Pierre-Marie Girard (members of the data and safety monitoring board, chaired by Peter Godfrey-Faussett) for their analysis of the trial progress and advice; and Jean-François Delfraissy for continuous support and helpful advice. This article is dedicated to the memory of Stephen D. Lawn, vice coinvestigator of the trial, whose work on tuberculosis–HIV coinfection still guides us to improve the care of severely immunosuppressed persons.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1910708_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1910708/suppl_file/nejmoa1910708_protocol.pdf" download="nejmoa1910708_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1910708_protocol.pdf" data-doi="10.1056/NEJMoa1910708">Download</a></li><li>2.24 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1910708_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1910708/suppl_file/nejmoa1910708_appendix.pdf" download="nejmoa1910708_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1910708_appendix.pdf" data-doi="10.1056/NEJMoa1910708">Download</a></li><li>1003.04 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1910708_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1910708/suppl_file/nejmoa1910708_disclosures.pdf" download="nejmoa1910708_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1910708_disclosures.pdf" data-doi="10.1056/NEJMoa1910708">Download</a></li><li>291.29 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1910708_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1910708/suppl_file/nejmoa1910708_data-sharing.pdf" download="nejmoa1910708_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1910708_data-sharing.pdf" data-doi="10.1056/NEJMoa1910708">Download</a></li><li>69.51 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Global tuberculosis report 2019. Geneva: World Health Organization, 2019.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+tuberculosis+report+2019&amp;publication_year=2019" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r1-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of death from a single infectious agent. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] immunodeficiency virus (HIV) infection. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Chrétien J. Tuberculosis and HIV: the cursed duet. <em>Bull Int Union Tuberc Lung Dis</em> 1990;65:25-28.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2350606/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tuberculosis+and+HIV%3A+the+cursed+duet.&amp;publication_year=1990&amp;journal=Bull+Int+Union+Tuberc+Lung+Dis&amp;pages=25-28&amp;pmid=2350606" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. <em>Lancet Infect Dis</em> 2018;18:1329-1349.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(18)30625-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30507459/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450899900030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global%2C+regional%2C+and+national+burden+of+tuberculosis%2C+1990-2016%3A+results+from+the+Global+Burden+of+Diseases%2C+Injuries%2C+and+Risk+Factors+2016+Study.&amp;publication_year=2018&amp;journal=Lancet+Infect+Dis&amp;pages=1329-1349&amp;doi=10.1016%2FS1473-3099%2818%2930625-X&amp;pmid=30507459" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Gupta A, Nadkarni G, Yang W-T, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. <em>PLoS One</em> 2011;6(12):e28691-e28691.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0028691" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22220193/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000300677000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+mortality+in+adults+initiating+antiretroviral+therapy+%28ART%29+in+low-+and+middle-income+countries+%28LMIC%29%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2011&amp;journal=PLoS+One&amp;pages=e28691-e28691&amp;doi=10.1371%2Fjournal.pone.0028691&amp;pmid=22220193" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] especially in sub-Saharan Africa and Asia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] group would be 14% at 24 weeks. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva: World Health Organization, 2010.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+intensified+tuberculosis+case+finding+and+isoniazid+preventive+therapy+for+people+living+with+HIV+in+resource+constrained+settings&amp;publication_year=2010" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for tuberculosis and other diseases. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with the use of the 2010 WHO questionnaire </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r5-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] symptoms according to the WHO criteria </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the WHO tuberculosis symptoms questionnaire </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization, 2013.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systematic+screening+for+active+tuberculosis%3A+principles+and+recommendations&amp;publication_year=2013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. <em>Int J Tuberc Lung Dis</em> 2010;14:1295-1302.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20843421/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282710700012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Significant+variation+in+presentation+of+pulmonary+tuberculosis+across+a+high+resolution+of+CD4+strata.&amp;publication_year=2010&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=1295-1302&amp;pmid=20843421" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Avila D, Althoff KN, Mugglin C, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. <em>J Acquir Immune Defic Syndr</em> 2014;65(1):e8-e16.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAI.0b013e3182a39979" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24419071/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000335650200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immunodeficiency+at+the+start+of+combination+antiretroviral+therapy+in+low-%2C+middle-%2C+and+high-income+countries.&amp;publication_year=2014&amp;journal=J+Acquir+Immune+Defic+Syndr&amp;pages=e8-e16&amp;doi=10.1097%2FQAI.0b013e3182a39979&amp;pmid=24419071" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Gesesew HA, Ward P, Woldemichael K, Mwanri L. Late presentation for HIV care in Southwest Ethiopia in 2003-2015: prevalence, trend, outcomes and risk factors. <em>BMC Infect Dis</em> 2018;18:59-59.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s12879-018-2971-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29378523/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423736800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Late+presentation+for+HIV+care+in+Southwest+Ethiopia+in+2003-2015%3A+prevalence%2C+trend%2C+outcomes+and+risk+factors.&amp;publication_year=2018&amp;journal=BMC+Infect+Dis&amp;pages=59-59&amp;doi=10.1186%2Fs12879-018-2971-6&amp;pmid=29378523" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. <em>AIDS</em> 2008;22:1897-1908.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAD.0b013e32830007cd" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18784453/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000259680100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+mortality+among+adults+accessing+antiretroviral+treatment+programmes+in+sub-Saharan+Africa.&amp;publication_year=2008&amp;journal=AIDS&amp;pages=1897-1908&amp;doi=10.1097%2FQAD.0b013e32830007cd&amp;pmid=18784453" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Moore DM, Yiannoutsos CT, Musick BS, et al. Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. <em>J Acquir Immune Defic Syndr</em> 2011;58:289-296.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAI.0b013e3182303716" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21857358/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296383900020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Determinants+of+early+and+late+mortality+among+HIV-infected+individuals+receiving+home-based+antiretroviral+therapy+in+rural+Uganda.&amp;publication_year=2011&amp;journal=J+Acquir+Immune+Defic+Syndr&amp;pages=289-296&amp;doi=10.1097%2FQAI.0b013e3182303716&amp;pmid=21857358" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Kouanda S, Meda IB, Nikiema L, et al. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study. <em>AIDS Care</em> 2012;24:478-490.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/09540121.2011.630353" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22148973/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000303562500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Determinants+and+causes+of+mortality+in+HIV-infected+patients+receiving+antiretroviral+therapy+in+Burkina+Faso%3A+a+five-year+retrospective+cohort+study.&amp;publication_year=2012&amp;journal=AIDS+Care&amp;pages=478-490&amp;doi=10.1080%2F09540121.2011.630353&amp;pmid=22148973" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Marcy O, Laureillard D, Madec Y, et al. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. <em>Clin Infect Dis</em> 2014;59:435-445.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciu283" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24759827/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000342919700020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Causes+and+determinants+of+mortality+in+HIV-infected+adults+with+tuberculosis%3A+an+analysis+from+the+CAMELIA+ANRS+1295-CIPRA+KH001+randomized+trial.&amp;publication_year=2014&amp;journal=Clin+Infect+Dis&amp;pages=435-445&amp;doi=10.1093%2Fcid%2Fciu283&amp;pmid=24759827" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RMGJ. The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. <em>PLoS One</em> 2014;9(11):e112017-e112017.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0112017" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25391135/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349144400046" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+impact+of+antiretroviral+therapy+on+mortality+in+HIV+positive+people+during+tuberculosis+treatment%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2014&amp;journal=PLoS+One&amp;pages=e112017-e112017&amp;doi=10.1371%2Fjournal.pone.0112017&amp;pmid=25391135" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. <em>Lancet HIV</em> 2015;2(10):e438-e444.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2352-3018(15)00137-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26423651/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363794100013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Causes+of+hospital+admission+among+people+living+with+HIV+worldwide%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2015&amp;journal=Lancet+HIV&amp;pages=e438-e444&amp;doi=10.1016%2FS2352-3018%2815%2900137-X&amp;pmid=26423651" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. <em>J Int AIDS Soc</em> 2016;19:20714-20714.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7448/IAS.19.1.20714" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26765347/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000368094900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=TB+as+a+cause+of+hospitalization+and+in-hospital+mortality+among+people+living+with+HIV+worldwide%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2016&amp;journal=J+Int+AIDS+Soc&amp;pages=20714-20714&amp;doi=10.7448%2FIAS.19.1.20714&amp;pmid=26765347" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Janssen S, Schutz C, Ward AM, et al. Hemostatic changes associated with increased mortality rates in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. <em>J Infect Dis</em> 2017;215:247-258.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28363198/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397204100012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hemostatic+changes+associated+with+increased+mortality+rates+in+hospitalized+patients+with+HIV-associated+tuberculosis%3A+a+prospective+cohort+study.&amp;publication_year=2017&amp;journal=J+Infect+Dis&amp;pages=247-258&amp;pmid=28363198" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. <em>Lancet Infect Dis</em> 2012;12:201-209.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(11)70251-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22015305/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000300861400025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+accuracy+of+a+low-cost%2C+urine+antigen%2C+point-of-care+screening+assay+for+HIV-associated+pulmonary+tuberculosis+before+antiretroviral+therapy%3A+a+descriptive+study.&amp;publication_year=2012&amp;journal=Lancet+Infect+Dis&amp;pages=201-209&amp;doi=10.1016%2FS1473-3099%2811%2970251-1&amp;pmid=22015305" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of correctly diagnosing tuberculosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] advanced immunodeficiency has been shown. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Lawn SD, Ayles H, Egwaga S, et al. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. <em>Int J Tuberc Lung Dis</em> 2011;15:287-295.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21333094/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000287984200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Potential+utility+of+empirical+tuberculosis+treatment+for+HIV-infected+patients+with+advanced+immunodeficiency+in+high+TB-HIV+burden+settings.&amp;publication_year=2011&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=287-295&amp;pmid=21333094" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">McCarthy K, Fielding K, Churchyard GJ, Grant AD. Empiric tuberculosis treatment in South African primary health care facilities — for whom, where, when and why: implications for the development of tuberculosis diagnostic tests. <em>PLoS One</em> 2018;13(1):e0191608-e0191608.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0191608" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29364960/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423412500060" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Empiric+tuberculosis+treatment+in+South+African+primary+health+care+facilities+%E2%80%94+for+whom%2C+where%2C+when+and+why%3A+implications+for+the+development+of+tuberculosis+diagnostic+tests.&amp;publication_year=2018&amp;journal=PLoS+One&amp;pages=e0191608-e0191608&amp;doi=10.1371%2Fjournal.pone.0191608&amp;pmid=29364960" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for tuberculosis without using these tests. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] initiated in some health care settings. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. <em>JAMA</em> 2013;310:2191-2194.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2013.281053" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24141714/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327404400028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=World+Medical+Association+Declaration+of+Helsinki%3A+ethical+principles+for+medical+research+involving+human+subjects.&amp;publication_year=2013&amp;journal=JAMA&amp;pages=2191-2194&amp;doi=10.1001%2Fjama.2013.281053&amp;pmid=24141714" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content"><em>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH harmonised tripartite guideline. Guideline for good clinical practice E6 (R1)</em>. 2002 (<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r1-guideline-good-clinical-practice_en.pdf">https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r1-guideline-good-clinical-practice_en.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International+Conference+on+Harmonisation+of+Technical+Requirements+for+Registration+of+Pharmaceuticals+for+Human+Use%3A+ICH+harmonised+tripartite+guideline.+Guideline+for+good+clinical+practice+E6+%28R1%29&amp;publication_year=2002" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">National Institute of Allergy and Infectious Diseases, Division of AIDS. <em>Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1</em>. July 2017 (<a href="https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf">https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Division+of+AIDS+%28DAIDS%29+table+for+grading+the+severity+of+adult+and+pediatric+adverse+events%2C+corrected+version+2.1&amp;publication_year=2017" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] according to the Division of AIDS) </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r23-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] to the criteria of the Division of AIDS. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r23-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] according to the Division of AIDS </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. <em>Lancet Infect Dis</em> 2008;8:516-523.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(08)70184-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18652998/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000258024800021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tuberculosis-associated+immune+reconstitution+inflammatory+syndrome%3A+case+definitions+for+use+in+resource-limited+settings.&amp;publication_year=2008&amp;journal=Lancet+Infect+Dis&amp;pages=516-523&amp;doi=10.1016%2FS1473-3099%2808%2970184-1&amp;pmid=18652998" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Hosseinipour MC, Bisson GP, Miyahara S, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. <em>Lancet</em> 2016;387:1198-1209.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)00546-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27025337/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000372412000031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Empirical+tuberculosis+therapy+versus+isoniazid+in+adult+outpatients+with+advanced+HIV+initiating+antiretroviral+therapy+%28REMEMBER%29%3A+a+multicountry+open-label+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1198-1209&amp;doi=10.1016%2FS0140-6736%2816%2900546-8&amp;pmid=27025337" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Grant AD, Charalambous S, Tlali M, et al. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. <em>Lancet HIV</em> 2020;7(1):e27-e37.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2352-3018(19)30266-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31727580/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505806500012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Algorithm-guided+empirical+tuberculosis+treatment+for+people+with+advanced+HIV+%28TB+Fast+Track%29%3A+an+open-label%2C+cluster-randomised+trial.&amp;publication_year=2020&amp;journal=Lancet+HIV&amp;pages=e27-e37&amp;doi=10.1016%2FS2352-3018%2819%2930266-8&amp;pmid=31727580" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Manabe YC, Worodria W, van Leth F, et al. Prevention of early mortality by presumptive tuberculosis therapy study: an open label, randomized controlled trial. <em>Am J Trop Med Hyg</em> 2016;95:1265-1271.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4269/ajtmh.16-0239" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27928077/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400206900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prevention+of+early+mortality+by+presumptive+tuberculosis+therapy+study%3A+an+open+label%2C+randomized+controlled+trial.&amp;publication_year=2016&amp;journal=Am+J+Trop+Med+Hyg&amp;pages=1265-1271&amp;doi=10.4269%2Fajtmh.16-0239&amp;pmid=27928077" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker L-G, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. <em>AIDS</em> 2009;23:1875-1880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAD.0b013e32832e05c8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20108382/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000269908800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Urine+lipoarabinomannan+assay+for+tuberculosis+screening+before+antiretroviral+therapy+diagnostic+yield+and+association+with+immune+reconstitution+disease.&amp;publication_year=2009&amp;journal=AIDS&amp;pages=1875-1880&amp;doi=10.1097%2FQAD.0b013e32832e05c8&amp;pmid=20108382" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. <em>Clin Infect Dis</em> 2010;51:823-829.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1086/656282" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20735240/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000281583000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intensive+tuberculosis+screening+for+HIV-infected+patients+starting+antiretroviral+therapy+in+Durban%2C+South+Africa.&amp;publication_year=2010&amp;journal=Clin+Infect+Dis&amp;pages=823-829&amp;doi=10.1086%2F656282&amp;pmid=20735240" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. <em>PLoS Med</em> 2011;8(7):e1001067-e1001067.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.1001067" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21818180/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000293169700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Screening+for+HIV-associated+tuberculosis+and+rifampicin+resistance+before+antiretroviral+therapy+using+the+Xpert+MTB%2FRIF+assay%3A+a+prospective+study.&amp;publication_year=2011&amp;journal=PLoS+Med&amp;pages=e1001067-e1001067&amp;doi=10.1371%2Fjournal.pmed.1001067&amp;pmid=21818180" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Karat AS, Omar T, von Gottberg A, et al. Autopsy prevalence of tuberculosis and other potentially treatable infections among adults with advanced HIV enrolled in out-patient care in South Africa. <em>PLoS One</em> 2016;11(11):e0166158-e0166158.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0166158" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27829072/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387724300092" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Autopsy+prevalence+of+tuberculosis+and+other+potentially+treatable+infections+among+adults+with+advanced+HIV+enrolled+in+out-patient+care+in+South+Africa.&amp;publication_year=2016&amp;journal=PLoS+One&amp;pages=e0166158-e0166158&amp;doi=10.1371%2Fjournal.pone.0166158&amp;pmid=27829072" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in West African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. <em>Lancet Glob Health</em> 2017;5(11):e1080-e1089.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2214-109X(17)30372-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29025631/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+isoniazid+preventive+therapy+on+risk+of+death+in+West+African%2C+HIV-infected+adults+with+high+CD4+cell+counts%3A+long-term+follow-up+of+the+Temprano+ANRS+12136+trial.&amp;publication_year=2017&amp;journal=Lancet+Glob+Health&amp;pages=e1080-e1089&amp;doi=10.1016%2FS2214-109X%2817%2930372-8&amp;pmid=29025631" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Blanc F-X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. <em>N Engl J Med</em> 2011;365:1471-1481.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_34_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1910708&amp;key=10.1056%2FNEJMoa1013911&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22010913/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296009500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Earlier+versus+later+start+of+antiretroviral+therapy+in+HIV-infected+adults+with+tuberculosis.&amp;publication_year=2011&amp;journal=N+Engl+J+Med&amp;pages=1471-1481&amp;doi=10.1056%2FNEJMoa1013911&amp;pmid=22010913" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Lan NTN, Thu NTN, Barrail-Tran A, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. <em>PLoS One</em> 2014;9(1):e84866-e84866.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0084866" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24465443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330283100014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomised+pharmacokinetic+trial+of+rifabutin+with+lopinavir%2Fritonavir-antiretroviral+therapy+in+patients+with+HIV-associated+tuberculosis+in+Vietnam.&amp;publication_year=2014&amp;journal=PLoS+One&amp;pages=e84866-e84866&amp;doi=10.1371%2Fjournal.pone.0084866&amp;pmid=24465443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Jindani A, Borgulya G, de Patiño IW, et al. A randomised phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. <em>Int J Tuberc Lung Dis</em> 2016;20:832-838.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5588/ijtld.15.0577" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27155189/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375892600020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomised+phase+II+trial+to+evaluate+the+toxicity+of+high-dose+rifampicin+to+treat+pulmonary+tuberculosis.&amp;publication_year=2016&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=832-838&amp;doi=10.5588%2Fijtld.15.0577&amp;pmid=27155189" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. <em>N Engl J Med</em> 2015;373:808-822.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_37_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1910708&amp;key=10.1056%2FNEJMoa1507198&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26193126/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360171700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+trial+of+early+antiretrovirals+and+isoniazid+preventive+therapy+in+Africa.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=808-822&amp;doi=10.1056%2FNEJMoa1507198&amp;pmid=26193126" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/382/25"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">382</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">25</span></span> • <span property="datePublished">June 18, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2397</span>-<span property="pageEnd">2410</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: June 17, 2020</div><div><b class="core-label">Published in issue</b>: June 18, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/diagnostics" alt="View article keyword Diagnostics" data-interactiontype="article_recirculation_click">Diagnostics</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/hiv-aids" alt="View article keyword HIV/AIDS" data-interactiontype="article_recirculation_click">HIV/AIDS</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/tuberculosis" alt="View article keyword Tuberculosis" data-interactiontype="article_recirculation_click">Tuberculosis</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">François-Xavier</span> <span property="familyName">Blanc</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7644-2188" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-7644-2188</a></span>, <span property="author" typeof="Person"><span property="givenName">Anani D.</span> <span property="familyName">Badje</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maryline</span> <span property="familyName">Bonnet</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Delphine</span> <span property="familyName">Gabillard</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Eugène</span> <span property="familyName">Messou</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Conrad</span> <span property="familyName">Muzoora</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sovannarith</span> <span property="familyName">Samreth</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bang D.</span> <span property="familyName">Nguyen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Laurence</span> <span property="familyName">Borand</span>, <span property="honorificSuffix">Pharm.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anaïs</span> <span property="familyName">Domergue</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Delphine</span> <span property="familyName">Rapoud</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Naome</span> <span property="familyName">Natukunda</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sopheak</span> <span property="familyName">Thai</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sylvain</span> <span property="familyName">Juchet</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Serge P.</span> <span property="familyName">Eholié</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Stephen D.</span> <span property="familyName">Lawn</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Serge K.</span> <span property="familyName">Domoua</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xavier</span> <span property="familyName">Anglaret</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Didier</span> <span property="familyName">Laureillard</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-0104-9047" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-0104-9047</a></span>, for <span property="author" typeof="Person">the STATIS ANRS 12290 Trial Team<sup><a href="#fn2" role="doc-noteref">†</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Department of Respiratory Medicine, L’Institut du Thorax, Nantes University Hospital, and the Medical School, University of Nantes, Nantes (F.-X.B.), INSERM Unité 1219, University of Bordeaux, Bordeaux (A.D.B., D.G., X.A.), Relations Translationnelles sur le VIH et les Maladies Infectieuses, Institut de Recherche pour le Développement, University of Montpellier, INSERM (M.B.), and Research Unit 1058 Pathogenesis and Control Chronical Infections, INSERM, French Blood Center, University of Montpellier (D.L.), Montpellier, and the Department of Infectious and Tropical Diseases, Nîmes University Hospital, Nîmes (D.L.) — all in France; Programme ANRS (Agence Nationale de Recherches sur le Sida et les Hépatites Virales) Coopération Côte d’Ivoire, ANRS research site (A.D.B., E.M., S.J.), and Félix Houphouët-Boigny University (S.P.E., S.K.D.) — both in Abidjan, Ivory Coast; Epicentre (M.B., N.N.) and Mbarara University of Science and Technology (C.M.) — both in Mbarara, Uganda; the National Center for HIV/AIDS, Dermatology, and Sexually Transmitted Diseases (S.S.), Institut Pasteur du Cambodge (L.B.), and Sihanouk Hospital Center of Hope (S.T.) — all in Phnom Penh, Cambodia; Pham Ngoc Thach Hospital (B.D.N.) and ANRS, Pham Ngoc Thach Hospital (A.D., D.R.), Ho Chi Minh City, Vietnam; and the Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London (S.D.L.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Blanc at Service de Pneumologie, Hôpital G. et R. Laënnec, Centre Hospitalier Universitaire de Nantes, Blvd. J. Monod, F-44093 Nantes CEDEX 1, France, or at <a href="mailto:xavier.blanc@chu-nantes.fr">xavier.blanc@chu-nantes.fr</a>.</div><div role="doc-footnote"><div id="fn1" role="paragraph">Stephen D. Lawn, M.D., Ph.D., is deceased.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="fn2" role="paragraph">A list of investigators and members of the STATIS ANRS 12290 Trial Team is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn3" role="paragraph">Drs. Anglaret and Laureillard contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">30</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1910708" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="9697b3cf-bde3-7ff6-3399-8f93c592817d"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84207982" style="display:inline-block;">
                <img alt="Article has an altmetric score of 77" src="https://badges.altmetric.com/?size=320&amp;score=77&amp;types=mbcttfd1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84207982">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_9697b3cf-bde3-7ff6-3399-8f93c592817d" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84207982&amp;tab=news">
          Picked up by <b>4</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84207982&amp;tab=blogs">
          Blogged by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84207982&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84207982&amp;tab=twitter">
          Posted by <b>56</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84207982&amp;tab=facebook">
          On <b>3</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84207982&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84207982&amp;tab=guidelines">
          Referenced in <b>1</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>186</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d63293d0ae0308-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1910708"> <input type="hidden" name="downloadFileName" value="csp_382_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1910708%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-25%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="30" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Qianshi Zhang, </li><li class="list-inline-item cited-by__entry__author">Xu Dong, </li><li class="list-inline-item cited-by__entry__author">Pengqi Zhang, </li><li class="list-inline-item cited-by__entry__author">Dongyan Wang, </li><li class="list-inline-item cited-by__entry__author">Yifang Mei, </li></ul><span class="cited-by__entry__title">Rheumatoid Arthritis and Tuberculosis, </span><span class="cited-by__entry__series-title">International Journal of Rheumatic Diseases, </span><span class="cited-by__entry__volume"><strong>28</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/1756-185X.70090" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/1756-185X.70090</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/1756-185X.70090" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Graeme Meintjes, </li><li class="list-inline-item cited-by__entry__author">Gary Maartens, </li></ul><span class="cited-by__entry__title">HIV-Associated Tuberculosis, </span><span class="cited-by__entry__series-title">New England Journal of Medicine, </span><span class="cited-by__entry__volume"><strong>391</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(343-355), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="/doi/full/10.1056/NEJMra2308181" title="Abstract" target="_self" class="cited-by__entry__doi">/doi/full/10.1056/NEJMra2308181</a><div class="cited-by__entry__extra-links"><a href="/doi/full/10.1056/NEJMra2308181" target="_self" class="cited-by__entry__visitable">Abstract</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Coulibaly Songuigama, </li><li class="list-inline-item cited-by__entry__author">Abdulrahim A. Alzain, </li><li class="list-inline-item cited-by__entry__author">Koné Soleymane, </li><li class="list-inline-item cited-by__entry__author">Deto U. Jean-Paul N’Guessan, </li><li class="list-inline-item cited-by__entry__author">Brigitte Gicquel, </li><li class="list-inline-item cited-by__entry__author">Christophe Rochais, </li><li class="list-inline-item cited-by__entry__author">Patrick Dallemagne, </li><li class="list-inline-item cited-by__entry__author">Mahama Ouattara, </li></ul><span class="cited-by__entry__title">QSAR, Docking Studies and in Silico Admet Prediction of 1,10-Phenanthrolinone Derivatives with Antitubercular Activities, </span><span class="cited-by__entry__series-title">Journal of Biochemical Technology, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(17-25), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.51847/cop0vCTgXX" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.51847/cop0vCTgXX</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.51847/cop0vCTgXX" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">François-Xavier Blanc, </li></ul><span class="cited-by__entry__title">Tuberculose et infection par le virus de l’immunodéficience humaine&nbsp;: comment réduire la mortalité&nbsp;?, </span><span class="cited-by__entry__series-title">Bulletin de l'Académie Nationale de Médecine, </span><span class="cited-by__entry__volume"><strong>207</strong>, </span><span class="cited-by__entry__issue">8, </span><span class="cited-by__entry__page-range">(1044-1052), </span><span class="cited-by__entry__pub-date">(2023).</span><a href="https://doi.org/10.1016/j.banm.2023.07.007" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.banm.2023.07.007</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.banm.2023.07.007" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rachael M Burke, </li><li class="list-inline-item cited-by__entry__author">Nicholas Feasey, </li><li class="list-inline-item cited-by__entry__author">Ajay Rangaraj, </li><li class="list-inline-item cited-by__entry__author">Maria Ruano Camps, </li><li class="list-inline-item cited-by__entry__author">Graeme Meintjes, </li><li class="list-inline-item cited-by__entry__author">Wafaa M El-Sadr, </li><li class="list-inline-item cited-by__entry__author">Nathan Ford, </li></ul><span class="cited-by__entry__title">Ending AIDS deaths requires improvements in clinical care for people with advanced HIV disease who are seriously ill, </span><span class="cited-by__entry__series-title">The Lancet HIV, </span><span class="cited-by__entry__volume"><strong>10</strong>, </span><span class="cited-by__entry__issue">7, </span><span class="cited-by__entry__page-range">(e482-e484), </span><span class="cited-by__entry__pub-date">(2023).</span><a href="https://doi.org/10.1016/S2352-3018(23)00109-1" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/S2352-3018(23)00109-1</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/S2352-3018(23)00109-1" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Maryline Bonnet, </li><li class="list-inline-item cited-by__entry__author">Delphine Gabillard, </li><li class="list-inline-item cited-by__entry__author">Serge Domoua, </li><li class="list-inline-item cited-by__entry__author">Conrad Muzoora, </li><li class="list-inline-item cited-by__entry__author">Eugène Messou, </li><li class="list-inline-item cited-by__entry__author">Samreth Sovannarith, </li><li class="list-inline-item cited-by__entry__author">Duc Bang Nguyen, </li><li class="list-inline-item cited-by__entry__author">Anani Badje, </li><li class="list-inline-item cited-by__entry__author">Sylvain Juchet, </li><li class="list-inline-item cited-by__entry__author">Dim Bunnet, </li><li class="list-inline-item cited-by__entry__author">Laurence Borand, </li><li class="list-inline-item cited-by__entry__author">Naome Natukunda, </li><li class="list-inline-item cited-by__entry__author">Thị Hong Tran, </li><li class="list-inline-item cited-by__entry__author">Xavier Anglaret, </li><li class="list-inline-item cited-by__entry__author">Didier Laureillard, </li><li class="list-inline-item cited-by__entry__author">François-Xavier Blanc, </li><li class="list-inline-item cited-by__entry__author">Kakou Aka, </li><li class="list-inline-item cited-by__entry__author">Eba Aoussi, </li><li class="list-inline-item cited-by__entry__author">Emmanuel Bissagnene, </li><li class="list-inline-item cited-by__entry__author">Serge Eholié, </li><li class="list-inline-item cited-by__entry__author">Frédéric Ello, </li><li class="list-inline-item cited-by__entry__author">Gustave Nzunetu, </li><li class="list-inline-item cited-by__entry__author">Cyprien Rabe, </li><li class="list-inline-item cited-by__entry__author">Baba Sidibé, </li><li class="list-inline-item cited-by__entry__author">Florence Adjé, </li><li class="list-inline-item cited-by__entry__author">Boris Ahonou, </li><li class="list-inline-item cited-by__entry__author">Jacqueline Amani, </li><li class="list-inline-item cited-by__entry__author">Amani Anzian, </li><li class="list-inline-item cited-by__entry__author">Anicet Assoua, </li><li class="list-inline-item cited-by__entry__author">Lucien Ayemou, </li><li class="list-inline-item cited-by__entry__author">Glao Diomandé, </li><li class="list-inline-item cited-by__entry__author">Etienne Etilé, </li><li class="list-inline-item cited-by__entry__author">Joachim Gnokoro, </li><li class="list-inline-item cited-by__entry__author">Jeannot Goli, </li><li class="list-inline-item cited-by__entry__author">Patrice Gouesse, </li><li class="list-inline-item cited-by__entry__author">Loukou Kati-Coulibaly, </li><li class="list-inline-item cited-by__entry__author">Lambert Konan, </li><li class="list-inline-item cited-by__entry__author">Edwige Konan, </li><li class="list-inline-item cited-by__entry__author">Francis Kouadio, </li><li class="list-inline-item cited-by__entry__author">Martial Kouakou, </li><li class="list-inline-item cited-by__entry__author">Aristide Kouamé, </li><li class="list-inline-item cited-by__entry__author">Georgette Labibi, </li><li class="list-inline-item cited-by__entry__author">Marie Cécile Lathro, </li><li class="list-inline-item cited-by__entry__author">Marie-Pascale Nogbout, </li><li class="list-inline-item cited-by__entry__author">Lucie N’Dry, </li><li class="list-inline-item cited-by__entry__author">Amah Tchehy, </li><li class="list-inline-item cited-by__entry__author">Ida Zadi, </li><li class="list-inline-item cited-by__entry__author">Hugues Ahiboh, </li><li class="list-inline-item cited-by__entry__author">Arlette Emieme, </li><li class="list-inline-item cited-by__entry__author">André Inwoley, </li><li class="list-inline-item cited-by__entry__author">Mathieu Kabran, </li><li class="list-inline-item cited-by__entry__author">Hervé Menan, </li><li class="list-inline-item cited-by__entry__author">Timothée Ouassa, </li><li class="list-inline-item cited-by__entry__author">Thomas-d’Aquin Toni, </li><li class="list-inline-item cited-by__entry__author">Raymond N’Guessan, </li><li class="list-inline-item cited-by__entry__author">Adrienne Aboua, </li><li class="list-inline-item cited-by__entry__author">Irmine Ahyi, </li><li class="list-inline-item cited-by__entry__author">Adoulaye Cissé, </li><li class="list-inline-item cited-by__entry__author">Christine Danel, </li><li class="list-inline-item cited-by__entry__author">Allé Baba DiengRomuald Konan, </li><li class="list-inline-item cited-by__entry__author">Célestin N’Chot, </li><li class="list-inline-item cited-by__entry__author">Larissa N’Guessan Koffi, </li><li class="list-inline-item cited-by__entry__author">Sylvie Konan, </li><li class="list-inline-item cited-by__entry__author">Suzanne Kouadio, </li><li class="list-inline-item cited-by__entry__author">Gérard Menan, </li><li class="list-inline-item cited-by__entry__author">Raoul Moh, </li><li class="list-inline-item cited-by__entry__author">Bertine Siloué, </li><li class="list-inline-item cited-by__entry__author">Cyril Yao-Yapi, </li><li class="list-inline-item cited-by__entry__author">Hillary Aheisibwe, </li><li class="list-inline-item cited-by__entry__author">Rinah Arinaitwe, </li><li class="list-inline-item cited-by__entry__author">Syson Atuhaire, </li><li class="list-inline-item cited-by__entry__author">Claire Kesande, </li><li class="list-inline-item cited-by__entry__author">Isaac Ampaire Isaac, </li><li class="list-inline-item cited-by__entry__author">Rodgers Kajabwangu, </li><li class="list-inline-item cited-by__entry__author">Stella Kyasiimire, </li><li class="list-inline-item cited-by__entry__author">Rose Kyarimpa, </li><li class="list-inline-item cited-by__entry__author">Doreen Mpeirwe, </li><li class="list-inline-item cited-by__entry__author">Gaudioza Mugabirwe, </li><li class="list-inline-item cited-by__entry__author">Margret Nansumba, </li><li class="list-inline-item cited-by__entry__author">Eva Natukunda, </li><li class="list-inline-item cited-by__entry__author">Teddy Namubiru, </li><li class="list-inline-item cited-by__entry__author">Masturah Nakanwagi, </li><li class="list-inline-item cited-by__entry__author">Junenal Nkeramahame, </li><li class="list-inline-item cited-by__entry__author">Miria Nyangoma, </li><li class="list-inline-item cited-by__entry__author">Colman Tayebwa, </li><li class="list-inline-item cited-by__entry__author">Patrick Orikiriza, </li><li class="list-inline-item cited-by__entry__author">Ivan Taremwa Mugisha, </li><li class="list-inline-item cited-by__entry__author">Esther Turyashemererwa, </li><li class="list-inline-item cited-by__entry__author">Deborah Nanjebe, </li><li class="list-inline-item cited-by__entry__author">Thadeous Turuho, </li><li class="list-inline-item cited-by__entry__author">Aisha Nalusaji, </li><li class="list-inline-item cited-by__entry__author">Arnold Ayabare, </li><li class="list-inline-item cited-by__entry__author">Ronald Kabanda, </li><li class="list-inline-item cited-by__entry__author">Kennedy Kassaza, </li><li class="list-inline-item cited-by__entry__author">and Sulaiman Muwanga, </li><li class="list-inline-item cited-by__entry__author">Chi Vun Mean, </li><li class="list-inline-item cited-by__entry__author">Penh Sun Ly, </li><li class="list-inline-item cited-by__entry__author">Daly Chea, </li><li class="list-inline-item cited-by__entry__author">Chandara Mom, </li><li class="list-inline-item cited-by__entry__author">Sophana Pich, </li><li class="list-inline-item cited-by__entry__author">Sandap Sar, </li><li class="list-inline-item cited-by__entry__author">Vannary Bun, </li><li class="list-inline-item cited-by__entry__author">Kuong Chan, </li><li class="list-inline-item cited-by__entry__author">Virin Chhneang, </li><li class="list-inline-item cited-by__entry__author">Chheng Kong Chhum, </li><li class="list-inline-item cited-by__entry__author">Samnang Khiev, </li><li class="list-inline-item cited-by__entry__author">Setha Lim Sreng, </li><li class="list-inline-item cited-by__entry__author">Nary Long, </li><li class="list-inline-item cited-by__entry__author">Makara Ly, </li><li class="list-inline-item cited-by__entry__author">Suon Sopheak Ma, </li><li class="list-inline-item cited-by__entry__author">Kimcolin Mao, </li><li class="list-inline-item cited-by__entry__author">Panharoat Men, </li><li class="list-inline-item cited-by__entry__author">Sovannary Mol, </li><li class="list-inline-item cited-by__entry__author">Vandoeun Nhem, </li><li class="list-inline-item cited-by__entry__author">Navy Nin, </li><li class="list-inline-item cited-by__entry__author">Moeung Roeun, </li><li class="list-inline-item cited-by__entry__author">Manith So, </li><li class="list-inline-item cited-by__entry__author">Phal Sok, </li><li class="list-inline-item cited-by__entry__author">Sovannara Song, </li><li class="list-inline-item cited-by__entry__author">Mary Sos, </li><li class="list-inline-item cited-by__entry__author">undefined Sotheara, </li><li class="list-inline-item cited-by__entry__author">undefined Thim, </li><li class="list-inline-item cited-by__entry__author">Narith Uk, </li><li class="list-inline-item cited-by__entry__author">Sokha Um, </li><li class="list-inline-item cited-by__entry__author">Tan Eang Mao, </li><li class="list-inline-item cited-by__entry__author">Che Yanith, </li><li class="list-inline-item cited-by__entry__author">Socheat Chim, </li><li class="list-inline-item cited-by__entry__author">Bun Than Chum, </li><li class="list-inline-item cited-by__entry__author">Doung Dara, </li><li class="list-inline-item cited-by__entry__author">Chanthy Din, </li><li class="list-inline-item cited-by__entry__author">Panha Eng, </li><li class="list-inline-item cited-by__entry__author">Putheary Hang, </li><li class="list-inline-item cited-by__entry__author">Savorn Im, </li><li class="list-inline-item cited-by__entry__author">Huy Keath, </li><li class="list-inline-item cited-by__entry__author">Karona Keo, </li><li class="list-inline-item cited-by__entry__author">Sok Lida Khem, </li><li class="list-inline-item cited-by__entry__author">Phirum Lay, </li><li class="list-inline-item cited-by__entry__author">Phalla Leng, </li><li class="list-inline-item cited-by__entry__author">Chiv Hun Oeung, </li><li class="list-inline-item cited-by__entry__author">Kalyan Ouk, </li><li class="list-inline-item cited-by__entry__author">Reaksmey Pe, </li><li class="list-inline-item cited-by__entry__author">Thong Phe, </li><li class="list-inline-item cited-by__entry__author">Bunthy Phoung, </li><li class="list-inline-item cited-by__entry__author">Mono Rouen, </li><li class="list-inline-item cited-by__entry__author">Sok Leang San, </li><li class="list-inline-item cited-by__entry__author">Sophy Sek, </li><li class="list-inline-item cited-by__entry__author">Teav Sina, </li><li class="list-inline-item cited-by__entry__author">Pichsovannary Srey, </li><li class="list-inline-item cited-by__entry__author">Seakly Sun, </li><li class="list-inline-item cited-by__entry__author">Sopheak Thai, </li><li class="list-inline-item cited-by__entry__author">Chhun Heng Veng, </li><li class="list-inline-item cited-by__entry__author">Young Suntouch, </li><li class="list-inline-item cited-by__entry__author">Sokleaph Cheng, </li><li class="list-inline-item cited-by__entry__author">Seiha Heng, </li><li class="list-inline-item cited-by__entry__author">Alexandra Kerléguer, </li><li class="list-inline-item cited-by__entry__author">Morina Hek, </li><li class="list-inline-item cited-by__entry__author">Brembrey Him, </li><li class="list-inline-item cited-by__entry__author">Monorea Keo, </li><li class="list-inline-item cited-by__entry__author">Boraneath Nang, </li><li class="list-inline-item cited-by__entry__author">Sophea Suom, </li><li class="list-inline-item cited-by__entry__author">Sreymom Thaan, </li><li class="list-inline-item cited-by__entry__author">Ho Chi Minh City, </li><li class="list-inline-item cited-by__entry__author">Le Minh Tri Dang, </li><li class="list-inline-item cited-by__entry__author">Quoc Dung Lam, </li><li class="list-inline-item cited-by__entry__author">Hong Ngoc Le, </li><li class="list-inline-item cited-by__entry__author">Thi Hieu Nguyen, </li><li class="list-inline-item cited-by__entry__author">Thi Hong Nguyen, </li><li class="list-inline-item cited-by__entry__author">Huu Minh Nguyen, </li><li class="list-inline-item cited-by__entry__author">Van Song Nguyen, </li><li class="list-inline-item cited-by__entry__author">Ha Uyen Nguyen, </li><li class="list-inline-item cited-by__entry__author">Nhu Viet Nguyen, </li><li class="list-inline-item cited-by__entry__author">Thi Bich Yen Nguyen, </li><li class="list-inline-item cited-by__entry__author">Thi Tuong Vy Pham, </li><li class="list-inline-item cited-by__entry__author">Ngoc Thach Tran, </li><li class="list-inline-item cited-by__entry__author">Pham Phuong Thao Tran, </li><li class="list-inline-item cited-by__entry__author">My Huong To, </li><li class="list-inline-item cited-by__entry__author">Huu Lân Nguyen, </li><li class="list-inline-item cited-by__entry__author">Thi Quynh Anh, </li><li class="list-inline-item cited-by__entry__author">undefined Nguyen, </li><li class="list-inline-item cited-by__entry__author">Hung Cuong Pham, </li><li class="list-inline-item cited-by__entry__author">Thi Thuy Nga Nguyen, </li><li class="list-inline-item cited-by__entry__author">Kim Ung Quach, </li><li class="list-inline-item cited-by__entry__author">Thi Thu Van Tieu, </li><li class="list-inline-item cited-by__entry__author">Ngoc Lan Nguyen, </li><li class="list-inline-item cited-by__entry__author">Thi Cao Van Nguyen, </li><li class="list-inline-item cited-by__entry__author">Huu Loc Tran, </li><li class="list-inline-item cited-by__entry__author">Xuan Thinh Vu, </li><li class="list-inline-item cited-by__entry__author">Khanh Thu Huynh, </li><li class="list-inline-item cited-by__entry__author">Que Anh Luong, </li><li class="list-inline-item cited-by__entry__author">Thi Xuan Lien Truong, </li><li class="list-inline-item cited-by__entry__author">Thi Thanh Dinh, </li><li class="list-inline-item cited-by__entry__author">Anaïs Domergue, </li><li class="list-inline-item cited-by__entry__author">Frédérique Guiroy, </li><li class="list-inline-item cited-by__entry__author">Quoc Khanh Le, </li><li class="list-inline-item cited-by__entry__author">Delphine Rapoud, </li><li class="list-inline-item cited-by__entry__author">Thi Hai Ly Tran, </li><li class="list-inline-item cited-by__entry__author">Jérôme Le Carrou, </li><li class="list-inline-item cited-by__entry__author">Sophie Karcher, </li><li class="list-inline-item cited-by__entry__author">Gwenaëlle Clouet, </li><li class="list-inline-item cited-by__entry__author">Stephen D Lawn, </li></ul><span class="cited-by__entry__title">High Performance of Systematic Combined Urine Liboarabinomannan Test and Sputum Xpert MTB/RIF for Tuberculosis Screening in Severely Immunosuppressed Ambulatory Adults With Human Immunodeficiency Virus, </span><span class="cited-by__entry__series-title">Clinical Infectious Diseases, </span><span class="cited-by__entry__volume"><strong>77</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(112-119), </span><span class="cited-by__entry__pub-date">(2023).</span><a href="https://doi.org/10.1093/cid/ciad125" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/cid/ciad125</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/cid/ciad125" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rachael M. Burke, </li><li class="list-inline-item cited-by__entry__author">Hussein H. Twabi, </li><li class="list-inline-item cited-by__entry__author">Cheryl Johnston, </li><li class="list-inline-item cited-by__entry__author">Marriott Nliwasa, </li><li class="list-inline-item cited-by__entry__author">Ankur Gupta-Wright, </li><li class="list-inline-item cited-by__entry__author">Katherine Fielding, </li><li class="list-inline-item cited-by__entry__author">Nathan Ford, </li><li class="list-inline-item cited-by__entry__author">Peter MacPherson, </li><li class="list-inline-item cited-by__entry__author">Elizabeth L. Corbett, </li></ul><span class="cited-by__entry__title">Interventions to reduce deaths in people living with HIV admitted to hospital in low- and middle-income countries: A systematic review, </span><span class="cited-by__entry__series-title">PLOS Global Public Health, </span><span class="cited-by__entry__volume"><strong>3</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(e0001557), </span><span class="cited-by__entry__pub-date">(2023).</span><a href="https://doi.org/10.1371/journal.pgph.0001557" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1371/journal.pgph.0001557</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1371/journal.pgph.0001557" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Guiqin Dai, </li><li class="list-inline-item cited-by__entry__author">Yuan Luo, </li><li class="list-inline-item cited-by__entry__author">Mingfeng Liao, </li><li class="list-inline-item cited-by__entry__author">Pengfei Zhang, </li><li class="list-inline-item cited-by__entry__author">Hong Pan, </li><li class="list-inline-item cited-by__entry__author">Ting Yin, </li><li class="list-inline-item cited-by__entry__author">Qianting Yang, </li><li class="list-inline-item cited-by__entry__author">Sirui Zheng, </li><li class="list-inline-item cited-by__entry__author">Jianhong Liao, </li><li class="list-inline-item cited-by__entry__author">Deliang Liu, </li><li class="list-inline-item cited-by__entry__author">Zhuojun He, </li><li class="list-inline-item cited-by__entry__author">Wenchang Zhao, </li><li class="list-inline-item cited-by__entry__author">Lijun Song, </li><li class="list-inline-item cited-by__entry__author">Pengfei Zhao, </li><li class="list-inline-item cited-by__entry__author">Lintao Cai, </li><li class="list-inline-item cited-by__entry__author">Zheng Zhang, </li><li class="list-inline-item cited-by__entry__author">Mingbin Zheng, </li></ul><span class="cited-by__entry__title">A cytoderm metabolic labeling AIEgen for rapid detection and intracellular ablation of Mycobacterium tuberculosis, </span><span class="cited-by__entry__series-title">Cell Reports Physical Science, </span><span class="cited-by__entry__volume"><strong>4</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(101238), </span><span class="cited-by__entry__pub-date">(2023).</span><a href="https://doi.org/10.1016/j.xcrp.2022.101238" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.xcrp.2022.101238</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.xcrp.2022.101238" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rebecca H Berhanu, </li><li class="list-inline-item cited-by__entry__author">Limakatso Lebina, </li><li class="list-inline-item cited-by__entry__author">Bareng A S Nonyane, </li><li class="list-inline-item cited-by__entry__author">Minja Milovanovic, </li><li class="list-inline-item cited-by__entry__author">Anthony Kinghorn, </li><li class="list-inline-item cited-by__entry__author">Lucy Connell, </li><li class="list-inline-item cited-by__entry__author">Sipho Nyathi, </li><li class="list-inline-item cited-by__entry__author">Katherine Young, </li><li class="list-inline-item cited-by__entry__author">Harry Hausler, </li><li class="list-inline-item cited-by__entry__author">Pren Naidoo, </li><li class="list-inline-item cited-by__entry__author">Zameer Brey, </li><li class="list-inline-item cited-by__entry__author">Kate Shearer, </li><li class="list-inline-item cited-by__entry__author">Leisha Genade, </li><li class="list-inline-item cited-by__entry__author">Neil A Martinson, </li></ul><span class="cited-by__entry__title">Yield of Facility-based Targeted Universal Testing for Tuberculosis With Xpert and Mycobacterial Culture in High-risk Groups Attending Primary Care Facilities in South Africa, </span><span class="cited-by__entry__series-title">Clinical Infectious Diseases, </span><span class="cited-by__entry__pub-date">(2023).</span><a href="https://doi.org/10.1093/cid/ciac965" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/cid/ciac965</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/cid/ciac965" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Corinne M Parker, </li><li class="list-inline-item cited-by__entry__author">Adolf W Karchmer, </li><li class="list-inline-item cited-by__entry__author">Margaret C Fisher, </li><li class="list-inline-item cited-by__entry__author">Kalimah M Muhammad, </li><li class="list-inline-item cited-by__entry__author">Patricia A Yu, </li></ul><span class="cited-by__entry__title">Safety of Antimicrobials for Postexposure Prophylaxis and Treatment of Anthrax: A Review, </span><span class="cited-by__entry__series-title">Clinical Infectious Diseases, </span><span class="cited-by__entry__volume"><strong>75</strong>, </span><span class="cited-by__entry__issue">Supplement_3, </span><span class="cited-by__entry__page-range">(S417-S431), </span><span class="cited-by__entry__pub-date">(2022).</span><a href="https://doi.org/10.1093/cid/ciac592" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/cid/ciac592</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/cid/ciac592" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1910708%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-25%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1910708" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1910708" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1910708.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1910708_f1.jpg"><img src="/cms/10.1056/NEJMoa1910708/asset/94fb6c6b-dfef-428c-8e05-4f714dc730df/assets/images/large/nejmoa1910708_f1.jpg" height="2398" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">The patients assigned to the guided-treatment group underwent tuberculosis screening by means of the Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography to determine whether treatment for tuberculosis should be implemented, and the patients assigned to the systematic-treatment group received empirical treatment for tuberculosis with the World Health Organization–recommended regimen of rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months. ALT denotes alanine aminotransferase, ART antiretroviral therapy, AST aspartate aminotransferase, and ULN upper limit of the normal range.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1910708_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1910708_f2.jpg"><img src="/cms/10.1056/NEJMoa1910708/asset/4530e058-0710-49d6-8031-55ae84941e63/assets/images/large/nejmoa1910708_f2.jpg" height="3438" width="2255" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Analysis of the Primary Composite End Point and End-Point Components.</div><div class="notes"><div role="doc-footnote">Shown are the Kaplan–Meier curves for the probability of the primary composite end point of death from any cause or invasive bacterial disease (Panel A) and the probability of the end-point components of death from any cause (Panel B) and invasive bacterial disease (defined as a bacteremia or clinical, biologic, or radiologic signs compatible with a bacterial infection of any solid organ or sterile space). In each panel, the inset shows the same data on an enlarged y axis. 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1910708_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1910708/asset/a1012336-f842-44e3-828b-167ef4fe914e/assets/images/large/nejmoa1910708_t1.jpg" height="3438" width="1572" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">Characteristic</th><th class="xxxx-borders">Guided Treatment<br>(N=525)</th><th class="xxxx-borders">Systematic Treatment <br>(N=522)</th></tr></thead><tbody><tr data-type="row"><td class="xxxx-borders hanging03 shading"><b>Baseline</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">221 (42.0)</td><td class="xxxx-borders">215 (41.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Median age (IQR) — yr</td><td class="xxxx-borders shading">35 (29–41)</td><td class="xxxx-borders shading">35 (29–41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Median body-mass index (IQR)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">19.6 (17.9–21.9)</td><td class="xxxx-borders">19.7 (17.8–21.9)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Karnofsky performance-status score — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">&lt;80</td><td class="xxxx-borders">27 (5.1)</td><td class="xxxx-borders">27 (5.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">≥80</td><td class="xxxx-borders shading">497 (94.7)</td><td class="xxxx-borders shading">494 (94.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Missing data</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">1 (0.2)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">WHO clinical stage — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Stage 1</td><td class="xxxx-borders">152 (29.0)</td><td class="xxxx-borders">146 (28.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">Stage 2</td><td class="xxxx-borders shading">132 (25.1)</td><td class="xxxx-borders shading">148 (28.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Stage &gt;2</td><td class="xxxx-borders">240 (45.7)</td><td class="xxxx-borders">227 (43.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">Missing data</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">1 (0.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Median CD4+ T-cell count (IQR) — cells/mm<sup>3</sup></td><td class="xxxx-borders">28 (12–56)</td><td class="xxxx-borders">32 (13–55)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">CD4+ T-cell count — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">≤50/mm<sup>3</sup></td><td class="xxxx-borders">370 (70.5)</td><td class="xxxx-borders">370 (70.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">51–99/mm<sup>3</sup></td><td class="xxxx-borders shading">155 (29.5)</td><td class="xxxx-borders shading">152 (29.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Median plasma HIV-1 RNA level (IQR) — log<sub>10</sub> copies/ml</td><td class="xxxx-borders">5.5 (5.2–5.8)</td><td class="xxxx-borders">5.4 (5.1–5.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Median hemoglobin level — g/dl</td><td class="xxxx-borders shading">11.5 (9.9–13.4)</td><td class="xxxx-borders shading">11.7 (9.9–13.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Positive plasma HBV surface antigen — no. (%)</td><td class="xxxx-borders">47 (9.0)</td><td class="xxxx-borders">48 (9.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Positive plasma HCV antibodies — no. (%)</td><td class="xxxx-borders shading">36 (6.9)</td><td class="xxxx-borders shading">35 (6.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Plasma ALT &gt;2.5× ULN — no. (%)</td><td class="xxxx-borders">49 (9.3)</td><td class="xxxx-borders">36 (6.9)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Patients with tuberculosis symptoms according to WHO criteria — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">No symptoms</td><td class="xxxx-borders">199 (37.9)</td><td class="xxxx-borders">196 (37.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">1 Symptom</td><td class="xxxx-borders shading">155 (29.5)</td><td class="xxxx-borders shading">150 (28.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">2 Symptoms</td><td class="xxxx-borders">90 (17.1)</td><td class="xxxx-borders">103 (19.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">3 Symptoms</td><td class="xxxx-borders shading">62 (11.8)</td><td class="xxxx-borders shading">58 (11.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">4 Symptoms</td><td class="xxxx-borders">18 (3.4)</td><td class="xxxx-borders">15 (2.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">Missing data</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">0</td></tr><tr data-type="row"><td class="xxxx-borders hanging03"><b>Follow-up</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Lost to follow-up — no. (%)</td><td class="xxxx-borders shading">11 (2.1)</td><td class="xxxx-borders shading">13 (2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Follow-up time — person-yr</td><td class="xxxx-borders">444</td><td class="xxxx-borders">442</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Initiated ART — no. (%)</td><td class="xxxx-borders shading">523 (99.6)</td><td class="xxxx-borders shading">510 (97.7)</td></tr><tr data-type="row"><td class="xxxx-borders hanging13">First-line regimen</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Tenofovir+lamivudine or emtricitabine+efavirenz</td><td class="xxxx-borders shading">490 (93.7)</td><td class="xxxx-borders shading">473 (92.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Zidovudine+lamivudine+efavirenz</td><td class="xxxx-borders">32 (6.1)</td><td class="xxxx-borders">35 (6.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Other<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">2 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Medication possession ratio &gt;95%<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">445 (85.1)</td><td class="xxxx-borders">434 (85.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Initiated treatment for tuberculosis — no. (%)</td><td class="xxxx-borders shading">93 (17.7)</td><td class="xxxx-borders shading">521 (99.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Completed 6 mo of treatment</td><td class="xxxx-borders">85 (91.4)</td><td class="xxxx-borders">497 (95.4)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Chest radiography performed — no. of patients/no. of tests</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">At day 0</td><td class="xxxx-borders">519/519</td><td class="xxxx-borders">514/516</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">After day 0 and before wk 24</td><td class="xxxx-borders shading">192/313</td><td class="xxxx-borders shading">488/870</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">After wk 24</td><td class="xxxx-borders">81/108</td><td class="xxxx-borders">156/180</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Urinary LAM test performed — no. of patients/no. of tests</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">At day 0</td><td class="xxxx-borders">524/524</td><td class="xxxx-borders">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">After day 0 and before wk 24</td><td class="xxxx-borders shading">146/183</td><td class="xxxx-borders shading">24/26</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">After wk 24</td><td class="xxxx-borders">43/54</td><td class="xxxx-borders">14/17</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Xpert MTB/RIF test performed on sputum sample — no. of patients/no. of tests</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">At day 0</td><td class="xxxx-borders">472/475</td><td class="xxxx-borders">0/0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13 shading" data-xml-align="left">After day 0 and before wk 24</td><td class="xxxx-borders shading">154/227</td><td class="xxxx-borders shading">37/49</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">After wk 24</td><td class="xxxx-borders">51/70</td><td class="xxxx-borders">19/30</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t1.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">None of the baseline characteristics differed significantly between strategies. Percentages may not total 100 because of rounding. ALT denotes alanine aminotransferase, ART antiretroviral therapy, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, IQR interquartile range, LAM lipoarabinomannan, ULN upper limit of the normal range, and WHO World Health Organization.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t1.jpg"><div class="label">§</div></a><div id="core-t1fn4" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t1.jpg">Tuberculosis symptoms according to the WHO criteria<sup></sup></a><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="core-body-ref-r5-3" href-manipulated="true" aria-label="Reference 5" data-to-manipulate="false">5</a> include cough, fever, weight loss, and night sweats.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">All 3 patients received tenofovir, lamivudine, and lopinavir–ritonavir.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">The medication possession ratio is the number of daily doses of antiretroviral drugs dispensed by the pharmacy to each patient, divided by that patient’s total follow-up time in days since the initiation of ART.</div></div></div></figcaption><figcaption><div class="caption">Characteristics of the Patients at Baseline and during Follow-up.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1910708/asset/0f8bef57-f563-4c8c-b877-b11c1d4f5d2b/assets/images/large/nejmoa1910708_t2.jpg" height="1968" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Clinical End Points</th><th class="txxx-borders" colspan="2"><span>Guided Treatment</span></th><th class="txxx-borders" colspan="2"><span>Systematic Treatment</span></th><th class="txxr-borders">Adjusted Hazard<br>Ratio (95% CI)<a href="#core-t2fn2" role="doc-noteref">†</a></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">No. of First Events</th><th class="xxxx-borders">Rate<br>(95% CI)<a href="#core-t2fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">No. of First Events</th><th class="xxxx-borders">Rate<br>(95% CI)<a href="#core-t2fn3" role="doc-noteref">‡</a></th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Primary end point at 24 wk: composite of death from any cause or invasive bacterial disease</td><td class="xxxx-borders shading">46</td><td class="xxxx-borders shading">20.3 (14.5–26.2)</td><td class="xxxx-borders shading">44</td><td class="xxxx-borders shading">19.4 (13.7–25.1)</td><td class="xxxr-borders shading">0.95 (0.63–1.44)<a href="#core-t2fn4" role="doc-noteref">§</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Secondary end points at 24 wk<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Death from any cause</td><td class="xxxx-borders shading">36</td><td class="xxxx-borders shading">15.6 (10.5–20.8)</td><td class="xxxx-borders shading">33</td><td class="xxxx-borders shading">14.4 (9.5–19.3)</td><td class="xxxr-borders shading">0.92 (0.57–1.47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Invasive bacterial disease</td><td class="xxxx-borders">15</td><td class="xxxx-borders">6.7 (3.7–11.0)</td><td class="xxxx-borders">18</td><td class="xxxx-borders">8.0 (4.7–12.6)</td><td class="xxxr-borders">1.19 (0.60–2.36)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Tuberculosis<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">93</td><td class="xxxx-borders shading">47.2 (37.6–56.8)</td><td class="xxxx-borders shading">15</td><td class="xxxx-borders shading">6.7 (3.7–11.0)</td><td class="xxxr-borders shading">0.15 (0.09–0.26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">IRIS</td><td class="xxxx-borders">57</td><td class="xxxx-borders">26.8 (19.8–33.7)</td><td class="xxxx-borders">17</td><td class="xxxx-borders">7.6 (4.4–12.1)</td><td class="xxxr-borders">0.39 (0.22–0.69)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">AIDS-defining events</td><td class="xxxx-borders shading">62</td><td class="xxxx-borders shading">29.3 (22.0–36.5)</td><td class="xxxx-borders shading">46</td><td class="xxxx-borders shading">21.3 (15.1–27.5)</td><td class="xxxr-borders shading">0.73 (0.50–1.06)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Grade 3 or 4 adverse events<a href="#core-t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">125</td><td class="xxxx-borders">65.5 (54.0–76.9)</td><td class="xxxx-borders">166</td><td class="xxxx-borders">94.3 (80.0–108.7)</td><td class="xxxr-borders">1.39 (1.11–1.76)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Grade 3 or 4 drug-related adverse events<a href="#core-t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">37</td><td class="xxxx-borders shading">16.9 (11.5–22.3)</td><td class="xxxx-borders shading">89</td><td class="xxxx-borders shading">44.7 (35.4–54.0)</td><td class="xxxr-borders shading">2.57 (1.75–3.78)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Secondary end points at 48 wk<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Composite of death from any cause or invasive bacterial disease</td><td class="xxxx-borders shading">58</td><td class="xxxx-borders shading">13.3 (9.9–16.7)</td><td class="xxxx-borders shading">56</td><td class="xxxx-borders shading">12.8 (9.5–16.2)</td><td class="xxxr-borders shading">0.97 (0.67–1.40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Death from any cause</td><td class="xxxx-borders">45</td><td class="xxxx-borders">10.1 (7.4–13.5)</td><td class="xxxx-borders">45</td><td class="xxxx-borders">10.2 (7.4–13.6)</td><td class="xxxr-borders">1.01 (0.67–1.52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Invasive bacterial disease</td><td class="xxxx-borders shading">19</td><td class="xxxx-borders shading">4.4 (2.7–6.9)</td><td class="xxxx-borders shading">22</td><td class="xxxx-borders shading">5.1 (3.2–7.7)</td><td class="xxxr-borders shading">1.15 (0.62–2.13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Tuberculosis<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">99</td><td class="xxxx-borders">26.2 (21.0–31.3)</td><td class="xxxx-borders">18</td><td class="xxxx-borders">4.2 (2.5–6.6)</td><td class="xxxr-borders">0.17 (0.10–0.28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">IRIS</td><td class="xxxx-borders shading">59</td><td class="xxxx-borders shading">14.4 (10.7–18.1)</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">3.9 (2.3–6.3)</td><td class="xxxr-borders shading">0.27 (0.16–0.47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">AIDS-defining events</td><td class="xxxx-borders">72</td><td class="xxxx-borders">17.7 (13.6–21.8)</td><td class="xxxx-borders">52</td><td class="xxxx-borders">12.6 (9.2–16.0)</td><td class="xxxr-borders">0.71 (0.49–1.01)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Grade 3 or 4 adverse events<a href="#core-t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">143</td><td class="xxxx-borders shading">39.8 (33.3–46.4)</td><td class="xxxx-borders shading">179</td><td class="xxxx-borders shading">54.7 (46.7–62.8)</td><td class="xxxr-borders shading">1.32 (1.06–1.65)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Grade 3 or 4 drug-related adverse events<a href="#core-t2fn7" role="doc-noteref">**</a></td><td class="xbxx-borders">39</td><td class="xbxx-borders">9.3 (6.4–12.2)</td><td class="xbxx-borders">94</td><td class="xbxx-borders">24.9 (19.9–30.0)</td><td class="xbxr-borders">2.59 (1.78–3.76)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t2.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t2.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">AIDS denotes acquired immunodeficiency syndrome, and IRIS immune reconstitution inflammatory syndrome.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The hazard ratios are for the systematic-treatment group as compared with the guided-treatment group and were adjusted for country (Ivory Coast, Uganda, Cambodia, or Vietnam) and baseline CD4+ T-cell count (≤50 per cubic millimeter or 51 to 99 per cubic millimeter).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Rate was calculated as the number of first events per 100 patient-years.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">P=0.82.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Because the trial protocol did not include a plan for adjustment for multiple comparisons, the results of the analyses of secondary end points are reported with point estimates and 95% confidence intervals, without P values, and the results cannot be used to infer effects.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">The end point of tuberculosis includes prevalent and incident cases. Of the 117 cases of tuberculosis, 54 included pulmonary involvement only, 18 included pulmonary and extra pulmonary involvement, and 45 included extrapulmonary involvement only.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t2.jpg"><div class="label">**</div></a><div id="core-t2fn7" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t2.jpg">Adverse events were graded according to the criteria of the Division of AIDS.<sup></sup></a><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="core-body-ref-r23-2" href-manipulated="true" aria-label="Reference 23" data-to-manipulate="false">23</a></div></div></div></figcaption><figcaption><div class="caption">Clinical End Points at 24 and 48 Weeks.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1910708/asset/6f403040-8ff5-45be-ba37-d52546370c5d/assets/images/large/nejmoa1910708_t3.jpg" height="3088" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Serious Adverse Event</th><th class="txxx-borders" colspan="2"><span>All Events<br>(495 Events)<a href="#core-t3fn1" role="doc-noteref">*</a></span></th><th class="txxr-borders" colspan="2"><span>Drug-Related Events<br>(150 Events)<a href="#core-t3fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Guided<br>Treatment</th><th class="xxxx-borders">Systematic<br>Treatment</th><th class="xxxx-borders">Guided<br>Treatment</th><th class="xxxr-borders">Systematic<br>Treatment</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of events</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Invasive bacterial infections</td><td class="xxxx-borders shading">20</td><td class="xxxx-borders shading">22</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Isolated bacteremia</td><td class="xxxx-borders">4</td><td class="xxxx-borders">9</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Bacterial pneumonia</td><td class="xxxx-borders shading">8</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Severe sepsis</td><td class="xxxx-borders">2</td><td class="xxxx-borders">4</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pyelonephritis</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Necrotizing fasciitis</td><td class="xxxx-borders">2</td><td class="xxxx-borders">0</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Bacterial enteritis</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Salpingitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Skin abscess</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Appendicitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Incident tuberculosis<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">50</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Other AIDS-defining illnesses</td><td class="xxxx-borders">31</td><td class="xxxx-borders">39</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cryptococcosis</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">10</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nontuberculous mycobacteriosis</td><td class="xxxx-borders">5</td><td class="xxxx-borders">2</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pneumocystis pneumonia</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Esophageal candidiasis</td><td class="xxxx-borders">3</td><td class="xxxx-borders">8</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cytomegalovirus retinitis</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Isosporiasis</td><td class="xxxx-borders">2</td><td class="xxxx-borders">2</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cryptosporidiosis</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Microsporidiosis</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Progressive multifocal leukoencephalopathy</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Kaposi’s sarcoma</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Solid tumors other than Kaposi’s sarcoma</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Wasting syndrome</td><td class="xxxx-borders">3</td><td class="xxxx-borders">4</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Other grade 3 or 4 adverse events</td><td class="xxxx-borders shading">119</td><td class="xxxx-borders shading">197</td><td class="xxxx-borders shading">45</td><td class="xxxr-borders shading">105</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Noninfectious transaminitis</td><td class="xxxx-borders">26</td><td class="xxxx-borders">43</td><td class="xxxx-borders">17</td><td class="xxxr-borders">39</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pruritus, rash, mucous ulcerations</td><td class="xxxx-borders shading">8</td><td class="xxxx-borders shading">35</td><td class="xxxx-borders shading">8</td><td class="xxxr-borders shading">34</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stevens–Johnson syndrome</td><td class="xxxx-borders">2</td><td class="xxxx-borders">3</td><td class="xxxx-borders">2</td><td class="xxxr-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Neutropenia</td><td class="xxxx-borders shading">16</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">5</td><td class="xxxr-borders shading">10</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Anemia</td><td class="xxxx-borders">7</td><td class="xxxx-borders">14</td><td class="xxxx-borders">1</td><td class="xxxr-borders">4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Thrombopenia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Bicytopenia or pancytopenia</td><td class="xxxx-borders">6</td><td class="xxxx-borders">3</td><td class="xxxx-borders">2</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Neuropsychiatric disorders</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">4</td><td class="xxxr-borders shading">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nonspecific acute fever</td><td class="xxxx-borders">5</td><td class="xxxx-borders">13</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonspecific kidney failure</td><td class="xxxx-borders shading">7</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">5</td><td class="xxxr-borders shading">4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2</td><td class="xxxx-borders">0</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hyperuricemia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gynecomastia</td><td class="xxxx-borders">1</td><td class="xxxx-borders">2</td><td class="xxxx-borders">1</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">36</td><td class="xxxx-borders shading">50</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Total</td><td class="xbxx-borders">220</td><td class="xbxx-borders">275</td><td class="xbxx-borders">45</td><td class="xbxr-borders">105</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t3.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t3.jpg"></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t3.jpg"><div class="label">*</div></a><div id="core-t3fn1" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t3.jpg">During follow-up, 495 serious adverse events occurred in 322 patients. Serious adverse events were defined as invasive bacterial diseases, incident tuberculosis, other AIDS-defining diseases, and other grade 3 or 4 events (classified according to the Division of AIDS<sup></sup></a><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="core-body-ref-r23-3" href-manipulated="true" aria-label="Reference 23" data-to-manipulate="false">23</a>).</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">The 150 serious drug-related adverse events are included with the 495 serious adverse events. Drug-relatedness was first assessed by an adjudication committee at the national level and was then reviewed by an international adjudication committee. The two committees were aware of the treatment-group assignments. A dash indicates that an event cannot be caused by medications.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Overall, 117 patients had tuberculosis: 50 cases were diagnosed at baseline (prevalent tuberculosis) and 67 were diagnosed during follow-up as new cases (incident tuberculosis). Only the 67 incident cases are shown in this table.</div></div></div></figcaption><figcaption><div class="caption">Distribution of Serious Adverse Events According to Treatment Group.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1910708_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1910708</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Global tuberculosis report 2019. Geneva: World Health Organization, 2019.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+tuberculosis+report+2019&amp;publication_year=2019" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r1-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of death from a single infectious agent. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] immunodeficiency virus (HIV) infection. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Chrétien J. Tuberculosis and HIV: the cursed duet. <em>Bull Int Union Tuberc Lung Dis</em> 1990;65:25-28.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2350606/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tuberculosis+and+HIV%3A+the+cursed+duet.&amp;publication_year=1990&amp;journal=Bull+Int+Union+Tuberc+Lung+Dis&amp;pages=25-28&amp;pmid=2350606" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. <em>Lancet Infect Dis</em> 2018;18:1329-1349.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(18)30625-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30507459/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450899900030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global%2C+regional%2C+and+national+burden+of+tuberculosis%2C+1990-2016%3A+results+from+the+Global+Burden+of+Diseases%2C+Injuries%2C+and+Risk+Factors+2016+Study.&amp;publication_year=2018&amp;journal=Lancet+Infect+Dis&amp;pages=1329-1349&amp;doi=10.1016%2FS1473-3099%2818%2930625-X&amp;pmid=30507459" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Gupta A, Nadkarni G, Yang W-T, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. <em>PLoS One</em> 2011;6(12):e28691-e28691.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0028691" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22220193/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000300677000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+mortality+in+adults+initiating+antiretroviral+therapy+%28ART%29+in+low-+and+middle-income+countries+%28LMIC%29%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2011&amp;journal=PLoS+One&amp;pages=e28691-e28691&amp;doi=10.1371%2Fjournal.pone.0028691&amp;pmid=22220193" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] especially in sub-Saharan Africa and Asia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] group would be 14% at 24 weeks. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva: World Health Organization, 2010.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+intensified+tuberculosis+case+finding+and+isoniazid+preventive+therapy+for+people+living+with+HIV+in+resource+constrained+settings&amp;publication_year=2010" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for tuberculosis and other diseases. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with the use of the 2010 WHO questionnaire </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r5-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] symptoms according to the WHO criteria </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the WHO tuberculosis symptoms questionnaire </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization, 2013.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systematic+screening+for+active+tuberculosis%3A+principles+and+recommendations&amp;publication_year=2013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. <em>Int J Tuberc Lung Dis</em> 2010;14:1295-1302.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20843421/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282710700012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Significant+variation+in+presentation+of+pulmonary+tuberculosis+across+a+high+resolution+of+CD4+strata.&amp;publication_year=2010&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=1295-1302&amp;pmid=20843421" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Avila D, Althoff KN, Mugglin C, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. <em>J Acquir Immune Defic Syndr</em> 2014;65(1):e8-e16.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAI.0b013e3182a39979" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24419071/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000335650200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immunodeficiency+at+the+start+of+combination+antiretroviral+therapy+in+low-%2C+middle-%2C+and+high-income+countries.&amp;publication_year=2014&amp;journal=J+Acquir+Immune+Defic+Syndr&amp;pages=e8-e16&amp;doi=10.1097%2FQAI.0b013e3182a39979&amp;pmid=24419071" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Gesesew HA, Ward P, Woldemichael K, Mwanri L. Late presentation for HIV care in Southwest Ethiopia in 2003-2015: prevalence, trend, outcomes and risk factors. <em>BMC Infect Dis</em> 2018;18:59-59.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s12879-018-2971-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29378523/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423736800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Late+presentation+for+HIV+care+in+Southwest+Ethiopia+in+2003-2015%3A+prevalence%2C+trend%2C+outcomes+and+risk+factors.&amp;publication_year=2018&amp;journal=BMC+Infect+Dis&amp;pages=59-59&amp;doi=10.1186%2Fs12879-018-2971-6&amp;pmid=29378523" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. <em>AIDS</em> 2008;22:1897-1908.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAD.0b013e32830007cd" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18784453/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000259680100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+mortality+among+adults+accessing+antiretroviral+treatment+programmes+in+sub-Saharan+Africa.&amp;publication_year=2008&amp;journal=AIDS&amp;pages=1897-1908&amp;doi=10.1097%2FQAD.0b013e32830007cd&amp;pmid=18784453" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Moore DM, Yiannoutsos CT, Musick BS, et al. Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. <em>J Acquir Immune Defic Syndr</em> 2011;58:289-296.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAI.0b013e3182303716" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21857358/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296383900020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Determinants+of+early+and+late+mortality+among+HIV-infected+individuals+receiving+home-based+antiretroviral+therapy+in+rural+Uganda.&amp;publication_year=2011&amp;journal=J+Acquir+Immune+Defic+Syndr&amp;pages=289-296&amp;doi=10.1097%2FQAI.0b013e3182303716&amp;pmid=21857358" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Kouanda S, Meda IB, Nikiema L, et al. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study. <em>AIDS Care</em> 2012;24:478-490.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/09540121.2011.630353" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22148973/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000303562500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Determinants+and+causes+of+mortality+in+HIV-infected+patients+receiving+antiretroviral+therapy+in+Burkina+Faso%3A+a+five-year+retrospective+cohort+study.&amp;publication_year=2012&amp;journal=AIDS+Care&amp;pages=478-490&amp;doi=10.1080%2F09540121.2011.630353&amp;pmid=22148973" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Marcy O, Laureillard D, Madec Y, et al. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. <em>Clin Infect Dis</em> 2014;59:435-445.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciu283" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24759827/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000342919700020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Causes+and+determinants+of+mortality+in+HIV-infected+adults+with+tuberculosis%3A+an+analysis+from+the+CAMELIA+ANRS+1295-CIPRA+KH001+randomized+trial.&amp;publication_year=2014&amp;journal=Clin+Infect+Dis&amp;pages=435-445&amp;doi=10.1093%2Fcid%2Fciu283&amp;pmid=24759827" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RMGJ. The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. <em>PLoS One</em> 2014;9(11):e112017-e112017.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0112017" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25391135/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349144400046" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+impact+of+antiretroviral+therapy+on+mortality+in+HIV+positive+people+during+tuberculosis+treatment%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2014&amp;journal=PLoS+One&amp;pages=e112017-e112017&amp;doi=10.1371%2Fjournal.pone.0112017&amp;pmid=25391135" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. <em>Lancet HIV</em> 2015;2(10):e438-e444.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2352-3018(15)00137-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26423651/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363794100013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Causes+of+hospital+admission+among+people+living+with+HIV+worldwide%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2015&amp;journal=Lancet+HIV&amp;pages=e438-e444&amp;doi=10.1016%2FS2352-3018%2815%2900137-X&amp;pmid=26423651" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. <em>J Int AIDS Soc</em> 2016;19:20714-20714.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7448/IAS.19.1.20714" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26765347/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000368094900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=TB+as+a+cause+of+hospitalization+and+in-hospital+mortality+among+people+living+with+HIV+worldwide%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2016&amp;journal=J+Int+AIDS+Soc&amp;pages=20714-20714&amp;doi=10.7448%2FIAS.19.1.20714&amp;pmid=26765347" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Janssen S, Schutz C, Ward AM, et al. Hemostatic changes associated with increased mortality rates in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. <em>J Infect Dis</em> 2017;215:247-258.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28363198/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397204100012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hemostatic+changes+associated+with+increased+mortality+rates+in+hospitalized+patients+with+HIV-associated+tuberculosis%3A+a+prospective+cohort+study.&amp;publication_year=2017&amp;journal=J+Infect+Dis&amp;pages=247-258&amp;pmid=28363198" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. <em>Lancet Infect Dis</em> 2012;12:201-209.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(11)70251-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22015305/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000300861400025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+accuracy+of+a+low-cost%2C+urine+antigen%2C+point-of-care+screening+assay+for+HIV-associated+pulmonary+tuberculosis+before+antiretroviral+therapy%3A+a+descriptive+study.&amp;publication_year=2012&amp;journal=Lancet+Infect+Dis&amp;pages=201-209&amp;doi=10.1016%2FS1473-3099%2811%2970251-1&amp;pmid=22015305" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of correctly diagnosing tuberculosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] advanced immunodeficiency has been shown. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Lawn SD, Ayles H, Egwaga S, et al. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. <em>Int J Tuberc Lung Dis</em> 2011;15:287-295.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21333094/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000287984200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Potential+utility+of+empirical+tuberculosis+treatment+for+HIV-infected+patients+with+advanced+immunodeficiency+in+high+TB-HIV+burden+settings.&amp;publication_year=2011&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=287-295&amp;pmid=21333094" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">McCarthy K, Fielding K, Churchyard GJ, Grant AD. Empiric tuberculosis treatment in South African primary health care facilities — for whom, where, when and why: implications for the development of tuberculosis diagnostic tests. <em>PLoS One</em> 2018;13(1):e0191608-e0191608.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0191608" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29364960/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423412500060" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Empiric+tuberculosis+treatment+in+South+African+primary+health+care+facilities+%E2%80%94+for+whom%2C+where%2C+when+and+why%3A+implications+for+the+development+of+tuberculosis+diagnostic+tests.&amp;publication_year=2018&amp;journal=PLoS+One&amp;pages=e0191608-e0191608&amp;doi=10.1371%2Fjournal.pone.0191608&amp;pmid=29364960" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for tuberculosis without using these tests. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] initiated in some health care settings. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. <em>JAMA</em> 2013;310:2191-2194.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2013.281053" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24141714/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327404400028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=World+Medical+Association+Declaration+of+Helsinki%3A+ethical+principles+for+medical+research+involving+human+subjects.&amp;publication_year=2013&amp;journal=JAMA&amp;pages=2191-2194&amp;doi=10.1001%2Fjama.2013.281053&amp;pmid=24141714" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content"><em>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH harmonised tripartite guideline. Guideline for good clinical practice E6 (R1)</em>. 2002 (<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r1-guideline-good-clinical-practice_en.pdf">https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r1-guideline-good-clinical-practice_en.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International+Conference+on+Harmonisation+of+Technical+Requirements+for+Registration+of+Pharmaceuticals+for+Human+Use%3A+ICH+harmonised+tripartite+guideline.+Guideline+for+good+clinical+practice+E6+%28R1%29&amp;publication_year=2002" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">National Institute of Allergy and Infectious Diseases, Division of AIDS. <em>Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1</em>. July 2017 (<a href="https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf">https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Division+of+AIDS+%28DAIDS%29+table+for+grading+the+severity+of+adult+and+pediatric+adverse+events%2C+corrected+version+2.1&amp;publication_year=2017" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] according to the Division of AIDS) </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r23-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] to the criteria of the Division of AIDS. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r23-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] according to the Division of AIDS </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. <em>Lancet Infect Dis</em> 2008;8:516-523.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(08)70184-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18652998/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000258024800021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tuberculosis-associated+immune+reconstitution+inflammatory+syndrome%3A+case+definitions+for+use+in+resource-limited+settings.&amp;publication_year=2008&amp;journal=Lancet+Infect+Dis&amp;pages=516-523&amp;doi=10.1016%2FS1473-3099%2808%2970184-1&amp;pmid=18652998" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Hosseinipour MC, Bisson GP, Miyahara S, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. <em>Lancet</em> 2016;387:1198-1209.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)00546-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27025337/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000372412000031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Empirical+tuberculosis+therapy+versus+isoniazid+in+adult+outpatients+with+advanced+HIV+initiating+antiretroviral+therapy+%28REMEMBER%29%3A+a+multicountry+open-label+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1198-1209&amp;doi=10.1016%2FS0140-6736%2816%2900546-8&amp;pmid=27025337" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Grant AD, Charalambous S, Tlali M, et al. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. <em>Lancet HIV</em> 2020;7(1):e27-e37.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2352-3018(19)30266-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31727580/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505806500012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Algorithm-guided+empirical+tuberculosis+treatment+for+people+with+advanced+HIV+%28TB+Fast+Track%29%3A+an+open-label%2C+cluster-randomised+trial.&amp;publication_year=2020&amp;journal=Lancet+HIV&amp;pages=e27-e37&amp;doi=10.1016%2FS2352-3018%2819%2930266-8&amp;pmid=31727580" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Manabe YC, Worodria W, van Leth F, et al. Prevention of early mortality by presumptive tuberculosis therapy study: an open label, randomized controlled trial. <em>Am J Trop Med Hyg</em> 2016;95:1265-1271.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4269/ajtmh.16-0239" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27928077/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400206900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prevention+of+early+mortality+by+presumptive+tuberculosis+therapy+study%3A+an+open+label%2C+randomized+controlled+trial.&amp;publication_year=2016&amp;journal=Am+J+Trop+Med+Hyg&amp;pages=1265-1271&amp;doi=10.4269%2Fajtmh.16-0239&amp;pmid=27928077" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker L-G, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. <em>AIDS</em> 2009;23:1875-1880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAD.0b013e32832e05c8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20108382/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000269908800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Urine+lipoarabinomannan+assay+for+tuberculosis+screening+before+antiretroviral+therapy+diagnostic+yield+and+association+with+immune+reconstitution+disease.&amp;publication_year=2009&amp;journal=AIDS&amp;pages=1875-1880&amp;doi=10.1097%2FQAD.0b013e32832e05c8&amp;pmid=20108382" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. <em>Clin Infect Dis</em> 2010;51:823-829.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1086/656282" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20735240/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000281583000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intensive+tuberculosis+screening+for+HIV-infected+patients+starting+antiretroviral+therapy+in+Durban%2C+South+Africa.&amp;publication_year=2010&amp;journal=Clin+Infect+Dis&amp;pages=823-829&amp;doi=10.1086%2F656282&amp;pmid=20735240" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. <em>PLoS Med</em> 2011;8(7):e1001067-e1001067.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.1001067" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21818180/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000293169700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Screening+for+HIV-associated+tuberculosis+and+rifampicin+resistance+before+antiretroviral+therapy+using+the+Xpert+MTB%2FRIF+assay%3A+a+prospective+study.&amp;publication_year=2011&amp;journal=PLoS+Med&amp;pages=e1001067-e1001067&amp;doi=10.1371%2Fjournal.pmed.1001067&amp;pmid=21818180" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Karat AS, Omar T, von Gottberg A, et al. Autopsy prevalence of tuberculosis and other potentially treatable infections among adults with advanced HIV enrolled in out-patient care in South Africa. <em>PLoS One</em> 2016;11(11):e0166158-e0166158.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0166158" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27829072/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387724300092" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Autopsy+prevalence+of+tuberculosis+and+other+potentially+treatable+infections+among+adults+with+advanced+HIV+enrolled+in+out-patient+care+in+South+Africa.&amp;publication_year=2016&amp;journal=PLoS+One&amp;pages=e0166158-e0166158&amp;doi=10.1371%2Fjournal.pone.0166158&amp;pmid=27829072" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in West African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. <em>Lancet Glob Health</em> 2017;5(11):e1080-e1089.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2214-109X(17)30372-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29025631/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+isoniazid+preventive+therapy+on+risk+of+death+in+West+African%2C+HIV-infected+adults+with+high+CD4+cell+counts%3A+long-term+follow-up+of+the+Temprano+ANRS+12136+trial.&amp;publication_year=2017&amp;journal=Lancet+Glob+Health&amp;pages=e1080-e1089&amp;doi=10.1016%2FS2214-109X%2817%2930372-8&amp;pmid=29025631" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Blanc F-X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. <em>N Engl J Med</em> 2011;365:1471-1481.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_34_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1910708&amp;key=10.1056%2FNEJMoa1013911&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22010913/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296009500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Earlier+versus+later+start+of+antiretroviral+therapy+in+HIV-infected+adults+with+tuberculosis.&amp;publication_year=2011&amp;journal=N+Engl+J+Med&amp;pages=1471-1481&amp;doi=10.1056%2FNEJMoa1013911&amp;pmid=22010913" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Lan NTN, Thu NTN, Barrail-Tran A, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. <em>PLoS One</em> 2014;9(1):e84866-e84866.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0084866" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24465443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330283100014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomised+pharmacokinetic+trial+of+rifabutin+with+lopinavir%2Fritonavir-antiretroviral+therapy+in+patients+with+HIV-associated+tuberculosis+in+Vietnam.&amp;publication_year=2014&amp;journal=PLoS+One&amp;pages=e84866-e84866&amp;doi=10.1371%2Fjournal.pone.0084866&amp;pmid=24465443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Jindani A, Borgulya G, de Patiño IW, et al. A randomised phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. <em>Int J Tuberc Lung Dis</em> 2016;20:832-838.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5588/ijtld.15.0577" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27155189/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375892600020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomised+phase+II+trial+to+evaluate+the+toxicity+of+high-dose+rifampicin+to+treat+pulmonary+tuberculosis.&amp;publication_year=2016&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=832-838&amp;doi=10.5588%2Fijtld.15.0577&amp;pmid=27155189" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. <em>N Engl J Med</em> 2015;373:808-822.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_37_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1910708&amp;key=10.1056%2FNEJMoa1507198&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26193126/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360171700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+trial+of+early+antiretrovirals+and+isoniazid+preventive+therapy+in+Africa.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=808-822&amp;doi=10.1056%2FNEJMoa1507198&amp;pmid=26193126" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 17, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2009679" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Empirical Antituberculosis Therapy in Advanced HIV Disease — Too Much, Too Late</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.E. Chaisson</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Boulder, Colorado</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885603/hematologist-oncologist-rocky-mountain-cancer-centers-boulder/?query=fjwp&amp;rid=5696">Hematologist/Oncologist - Rocky Mountain Cancer Centers Boulder</a></div></div><div class="nejm-widget_item"><div><span> Staten Island, New York</span></div><div><span>Urology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/401671/andrology-at-northwell-health-staten-island-university-hospital-/?query=fjwp&amp;rid=3059">Andrology at Northwell Health - Staten Island University Hospital </a></div></div><div class="nejm-widget_item"><div><span> Athens, Ohio</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887375/ob-gyn-hospitalist/?query=fjwf&amp;rid=49812">OB/GYN Hospitalist</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/674703/seeking-talented-neurologists-new-york-city-and-long-island-northwell-health/?query=fjwp&amp;rid=3059">Seeking Talented Neurologists - New York City &amp; Long Island - Northwell Health</a></div></div><div class="nejm-widget_item"><div><span> Pueblo, Colorado</span></div><div><span>Surgery, Vascular</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879647/physician-vascular-surgery/?query=fjwf&amp;rid=129661">Physician Vascular Surgery</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Dermatology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891189/physician-dermatology/?query=fjwf&amp;rid=385607">Physician - Dermatology</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1910708&amp;pubId=41288784&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d63293d0ae0308-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d63293d0ae0308-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d63293d0ae0308-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$634562110$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$634562110$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$634562110$--></div></div><div class="mlt-body"><!--?lit$634562110$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$634562110$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$634562110$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$634562110$-->Jan 30, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2400327?query=recirc_Semantic" target="_self">Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$634562110$-->L. Guglielmetti and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$634562110$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$634562110$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$634562110$-->Jul 25, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2308181?query=recirc_Semantic" target="_self">HIV-Associated Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$634562110$-->G. Meintjes and G. Maartens</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$634562110$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$634562110$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$634562110$-->Mar 09, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2212537?query=recirc_Semantic" target="_self">Treatment Strategy for Rifampin-Susceptible Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$634562110$-->N.I. Paton and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$634562110$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$634562110$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$634562110$-->Dec 22, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2117166?query=recirc_Semantic" target="_self">A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$634562110$-->B.-T. Nyang’wa and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$634562110$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$634562110$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$634562110$-->Oct 31, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2411285?query=recirc_Semantic" target="_self">HIV-Associated Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$634562110$--></div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1910708?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1910708" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1910708.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1910708"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp2005234" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>“We Signed Up for This!” — Student and Trainee Responses to the Covid-19 Pandemic</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2012410" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1910708_f1.jpg"><img src="/cms/10.1056/NEJMoa1910708/asset/94fb6c6b-dfef-428c-8e05-4f714dc730df/assets/images/large/nejmoa1910708_f1.jpg" height="2398" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">The patients assigned to the guided-treatment group underwent tuberculosis screening by means of the Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography to determine whether treatment for tuberculosis should be implemented, and the patients assigned to the systematic-treatment group received empirical treatment for tuberculosis with the World Health Organization–recommended regimen of rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months. ALT denotes alanine aminotransferase, ART antiretroviral therapy, AST aspartate aminotransferase, and ULN upper limit of the normal range.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1910708_f2.jpg"><img src="/cms/10.1056/NEJMoa1910708/asset/4530e058-0710-49d6-8031-55ae84941e63/assets/images/large/nejmoa1910708_f2.jpg" height="3438" width="2255" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Kaplan–Meier Analysis of the Primary Composite End Point and End-Point Components.</div><div class="notes"><div role="doc-footnote">Shown are the Kaplan–Meier curves for the probability of the primary composite end point of death from any cause or invasive bacterial disease (Panel A) and the probability of the end-point components of death from any cause (Panel B) and invasive bacterial disease (defined as a bacteremia or clinical, biologic, or radiologic signs compatible with a bacterial infection of any solid organ or sterile space). In each panel, the inset shows the same data on an enlarged y axis. 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Patients at Baseline and during Follow-up.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Clinical End Points at 24 and 48 Weeks.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Distribution of Serious Adverse Events According to Treatment Group.</div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/382/25" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 382 No. 25</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 18, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2007621" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.R. Mehra and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 18, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2012410" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J. Geleris and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 18, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2004413" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">K. Shitara and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1910708%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1910708&amp;pubId=41288784&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1910708%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1910708&amp;pubId=41288784&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id006206652546734581" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d63293d0ae0308-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d63293d0ae0308-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d63293d0ae0308-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d63293d0ae0308-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d63293d0ae0308-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d63293d0ae0308-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d63293d0ae0308-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d63293d0ae0308-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d63293d0ae0308-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d63293d0ae0308-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d63293cb770308',t:'MTc0OTUzMDQ5OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d63293cb770308&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-transactionid="4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" id="captureIFrame_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" target="captureIFrame_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="capture_screen"><input id="capture_signIn_js_version_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="js_version"><input id="capture_signIn_transactionId_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" type="hidden" class="capture_transactionId_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="capture_transactionId"><input id="capture_signIn_form_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="form"><input id="capture_signIn_flow_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="flow"><input id="capture_signIn_client_id_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="client_id"><input id="capture_signIn_redirect_uri_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="redirect_uri"><input id="capture_signIn_response_type_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="response_type"><input id="capture_signIn_flow_version_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="flow_version"><input id="capture_signIn_settings_version_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="settings_version"><input id="capture_signIn_locale_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="locale"><input id="capture_signIn_recaptcha_version_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_4kadzuuzuoyeb2pziyn13knl9priudiumavfdxnl" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><wwo-lyyguglxaytc></wwo-lyyguglxaytc><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1910708?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>